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Abstract of the Dissertation
Cyclotron Production and Biomedical Applications of the PET Isotope Manganese-52
by
Andrew Lake Wooten
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2016
Suzanne E. Lapi, Chair
Mark A. Anastasio, Co-Chair
Manganese is an important element for biomedical research because of its roles as an
essential micronutrient and as a neurotoxin from chronic elevated exposure, as well as the role of
manganese(II) as a paramagnetic core for contrast agents in T1-weighted magnetic resonance
imaging (MRI). Using a radiotracer of manganese provides excellent sensitivity for studying
these phenomena, but only

52

Mn met the criteria for our experiments: (1) a half-life (t1/2=5.6

days) that was long enough to examine timepoints over several days, (2) a half-life that was short
enough to emit sufficient counts for a realistic scan time, and (3) emitted radiation of a variety
and energy that were appropriate for existing pre-clinical imaging modalities. Manganese-52 is
well-suited for imaging with positron emission tomography (PET) because it emits positrons
with a low energy (Eβ+=242 keV), which improves spatial resolution, and with an acceptable
total abundance for positron emission (Iβ+=29.6%) for adequate signal. Manganese-52 was
produced on site by the

52

Cr(p,n)52Mn reaction by bombarding non-enriched chromium (52Cr:

83.8%) with ~13 MeV protons that were accelerated in the CS-15 cyclotron at Washington
University School of Medicine in St. Louis. Bombardments of stacks of thin chromium metal
foils were used to measure nuclear cross-sections for the

nat

Cr(p,x)52,52m,54Mn reactions, with

results that agreed closely to simulations and published results. Manganese-52 was separated

xv

chemically from bombarded chromium metal by cation- or anion-exchange chromatography. The
separated product was used in experiments that included biodistribution by injection or
inhalation, PET/CT or PET/MR in phantoms and rodents, and radiolabelling of a Mn(II)-based
contrast agent for T1-weighted MRI. To reduce radiation dose to production personnel, we
designed a remotely controlled, semi-automated module for the remote separation of 52Mn inside
a lead hot cell. This module was similar to other modules that we designed, built, and tested for
the routine, scaled-up production of larger quantities of the PET isotopes

89

Zr and

86

Y. We

anticipate that the module for 52Mn will be completed, routine production of greater quantities of
52

Mn will be achieved, and this radioisotope will continue to be used to study and image the

interesting aspects and behaviors of manganese chemistry.

xvi

Chapter 1. Introduction
1.1. The Paradigm of Molecular Imaging
The work in this dissertation includes non-imaging experiments related to the production
and validation of a radiotracer for manganese, but, ultimately, the goal is to develop a radiotracer
for manganese for in vivo nuclear imaging as an approach to molecular imaging. Radiotracers in
biological and medical experiments has roots extending back to the earliest days of radionuclide
production (Wagner, 2010) from cyclotrons (Ruben, et al., 1939) and nuclear reactors (Werner,
et al., 1949), but molecular imaging as a whole extends beyond radiotracers and nuclear imaging.
Only in recent decades, has the term molecular imaging been used and defined in 2007 as “[..]the
visualization, characterization, and measurement of biological processes at the molecular and
cellular levels in humans and other living systems.” (Mankoff, 2007). This definition goes on to
explain that molecular imaging frequently generates quantitative images in two- or threedimensions with time resolution and that this field is not limited to nuclear imaging, but also
includes approaches based on nuclear magnetic resonance spectroscopy and imaging, ultrasound,
optical luminescence imaging, and other imaging modalities (Mankoff, 2007).
One major advantage of molecular imaging for studying biological questions is that,
unlike in vitro and ex vivo assays, biological processes can be examined in vivo—intact in a
living organism. This is more realistic because cells are in their original microenvironment,
including biological feedback loops (Gambhir, 2010). The ideal molecular imaging modality
would have the ability to detect very low concentrations of molecular targets and to track cells,
image with excellent spatial and temporal resolution, provide completely quantitative results, be

useful for imaging targets anywhere within cells and tissues at any realistic depth, as well as
practical criteria of high throughput and low cost (Gambhir, 2010). Practically, the perfect
modality does not exist, so the advantages and disadvantages of various modalities are
considered when selecting an approach to a molecular imaging study.
Molecular imaging typically depends on endogenous or exogenous molecular imaging
agents that can generate imageable signal(s) that reflect the location and other biological
information inside an organism (Mankoff, 2007). Molecular imaging agents typically satisfy the
tracer principle (Vanbrocklin, 2010) that was originally described by de Hevesy (Hevesy, 1923),
which asserts that a probe in a small enough concentration will not disturb the (bio)chemistry of
the system to which it is being applied for study. Probes that satisfy the tracer criteria can be
trusted to provide information about a practically unperturbed system. Additionally, the chemical
toxicity of such probes is not significant for non-chronic use, which dramatically increases the
flexibility of selecting an imaging probe, such as radioisotopes of elements that would be toxic in
greater concentrations. The tracer principle applies most readily to nuclear imaging because most
biomedical radiotracers produce sufficient signal for detection and imaging from trace
concentrations, but the tracer principle can apply to probes for other modalities of molecular
imaging as well.
Frequently, the goal of developing a molecular imaging agent or other imaging technique
is to translate the agent into clinical practice, but such translation requires navigating significant
regulations associated with clinical studies (Gambhir, 2010). Some molecular imaging agents are
not suitable for clinical use for various reasons (Gambhir, 2010), such as chemical toxicity,
radiation dosimetry, attenuation of signal by human tissue, cost, or availability. Nevertheless,
some agents that are only used in animal models can make valuable contributions to basic

2

research by expanding knowledge of biological questions (Gambhir, 2010). The development of
52

Mn as a radiotracer for PET imaging of manganese likely fits into this category.

1.2. Motivations for Studying Manganese
There are at least three biomedical roles and applications of manganese that make this
element interesting for study, and they motivate the pursuit of quantitative detection and imaging
of manganese. These roles include manganese (1) as an essential micronutrient that serves as a
cofactor for important metalloenzymes, (2) as a neurotoxin that causes motor disorders following
chronic inhalation of manganese, and (3) as a contrast agent for manganese-enhance magnetic
resonance imaging (MEMRI). Although imaging of accumulated Mn(II) is possible by MRI,
quantitative measurement and quantitative imaging of manganese is difficult, and MRI and CT
contrast agents can require local concentrations as high as millimolar (10-3 M), compared to
concentrations as low as picomolar (10-12 M) for the nuclear emission imaging techniques
SPECT and PET (Lobatto, et al., 2011). The concentrations of contrast agents for MRI and CT
are high enough that toxicity needs to be considered; however, this is not the case at the
concentrations used for radiotracers for SPECT and PET.
The results presented from biological experiments in this dissertation (Chapter 3) could
be useful as supporting information for environmental and occupational regulations, for
designing PET studies utilizing 52Mn, and for predicting biodistribution of manganese-based MR
agents.

3

1.2.1. Natural Abundance of 52Mn
Manganese is a micronutrient that is essential for human life in only trace amounts
(Avila, et al., 2013; Averill and Eldredge, 2011). Ingestion of manganese is part of a healthy
human diet, and deficiency is rare (OSU/LPI, 2010). Existing primarily in the Mn(IV) oxidation
state in the earth’s crust (Greenwood and Earnshaw, 1997), manganese is the third most
abundant transition metal in the crust (TJNAF; Greenwood and Earnshaw, 1997), and is taken up
by plants, where it is stored in produce and nuts (USDA/ARS) and utilized in green leaves as an
oxidizer in photosynthesis (Greenwood and Earnshaw, 1997). Although manganese can form
complexes in more oxidation states than any other first-row transition metal (Brown, et al., 2000;
Greenwood and Earnshaw, 1997), Mn(II) is by far the most electrochemically stable oxidation
state for manganese (Greenwood and Earnshaw, 1997) and the state that is predominantly used
as an enzymatic cofactor. Nevertheless, free Mn(II) is efficiently cleared from the blood by the
liver for excretion (Gibbons, et al., 1976), so Mn in the blood is found as Mn(III) bound to
binding sites for Fe(III) on transferrin (Scheuhammer and Cherian, 1985; Gibbons, et al., 1976)
or as Mn(II) bound to other serum proteins (Lau and Sarkar, 1984).
In humans, manganese is principally utilized as a co-factor for metalloenzymes in
important biological processes, such as conversion of reactive oxygen species, gluconeogenesis,
and the urea cycle (OSU/LPI, 2010). The body distributes manganese to tissues throughout the
body (Yokel, 2009), where it can be taken into cells by transferrin-mediated endocytosis, the
divalent metal transporter (DMT-1), and/or voltage-gated calcium channels (Roth, 2009).
Manganese can also cross the blood-brain barrier by carrier-mediated transport (Yokel, 2009,
2006; Crossgrove, et al., 2003) and calcium-release activated channels (Yokel, 2009, 2006;
Crossgrove and Yokel, 2005), where at least one of its roles is to moderate cellular uptake of the
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neurotransmitter glutamate (Yin, et al., 2010; OSU/LPI, 2010). In this dissertation, we examine
the biodistribution of manganese using 52Mn as a radiotracer (Chapter 3).

1.2.2. Toxicology of Manganese
The necessity of manganese as a nutrient is sometimes overshadowed by its neurotoxic
effects, resulting in manganism (Avila, et al., 2013), a condition that was first described in 1837
(Couper, 1837). In mangansim, early-stage patients often present with psychiatric symptoms
(Racette, et al., 2012a; Laohaudomchok, et al., 2011; Guilarte, 2010; Burton and Guilarte, 2009;
Roth, 2006; Mergler, et al., 1994; Sjogren, et al., 1990; Rodier, 1955) that are sometimes referred
to as “manganese madness” (Calne, et al., 1994). Later-stage patients develop symptoms of
parkinsonism, including intellectual impairment, tremors, and rigidity similar to parkinsonism
(Cersosimo and Koller, 2006; Josephs, et al., 2005; Hudnell, 1999; Sjogren, et al., 1996; Calne,
et al., 1994; Mergler, et al., 1994; Rodier, 1955; Couper, 1837), with a few key differences from
idiopathic Parkinson’s disease. It is believed that manganism typically results from chronic
exposure to small doses of manganese, because manganese(II) chloride has relatively low acute
toxicity in rodent models: LD50=0.22-3.59 mmol/kg for intravenous injection (Gimi, et al., 2006;
Elizondo, et al., 1991; Wolf, et al., 1985), LD50=1 mmol/kg for intraperitoneal injection (Pan, et
al., 2010), and LD50=7.50 mmol/kg (tetrahydrate) for oral administration (MSDS, SigmaAldrich, 2015).
Nevertheless, neurotoxicity can result in animals or humans from chronic exposure to
manganese in the water supply (Elsner and Spangler, 2005; Kondakis, et al., 1989), in ephedrine
(methcathinone) produced using potassium permanganate (Sikk, et al., 2013; Sikk, et al., 2011;
Sikk, et al., 2010; de Bie, et al., 2007; Sanotsky, et al., 2007), in the farming fungicides maneb or
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mancozeb (J. Zhang, et al., 2003; Thiruchelvam, et al., 2000a; Thiruchelvam, et al., 2000b;
Meco, et al., 1994; Morato, et al., 1989; Ferraz, et al., 1988; Israeli, et al., 1983; Israeli, et al.), or
in gasoline containing the additive methylcyclopentadienyl manganese tricarbonyl (MMT)
(Zheng, et al., 2000; Komura and Sakamoto, 1994, 1992; Clay and Morris, 1989). These sources
have led government bodies to place limits on acceptable levels of non-occupational manganese
at 0.05-0.5 mg/L in drinking water (Australia Department of the Environment, 2015; Williams,
et al., 2012; U.S. E.P.A., 2009; Williams-Johnson, 1999) and 0.15-1,000 µg/m3 in air (Williams,
et al., 2012; Williams-Johnson, 1999).
However, certain types of metalworking can cause elevated risk of exposure to airborne
manganese, so regulations have been placed on workplace exposure to airborne manganese
(including from compounds, particles, and fumes) at 0.3-5 mg/m3 (Australia Department of the
Environment, 2015; Williams, et al., 2012; U.S. E.P.A., 2009; Williams-Johnson, 1999). Despite
a few epidemiology studies—including some sponsored by industry—that dispute the existence
of a link between metalworking and neurological disease (Fored, et al., 2006; Marsh and Gula,
2006; Fryzek, et al., 2005), there are still many reports of manganism in exposed workers
(Searles Nielsen, et al., 2015; Gonzalez-Cuyar, et al., 2014; Racette, et al., 2012b; Racette, et al.,
2012a; Harris, et al., 2011; Laohaudomchok, et al., 2011; Sriram, et al., 2010; Flynn and Susi,
2009; Marsh and Gula, 2006; Kenangil, et al., 2006; Fored, et al., 2006; Josephs, et al., 2005).
Studies in these workers have demonstrated hallmark symptoms of manganism, and the
accumulation of manganese in the brain can be so great that the current method for diagnosis of
manganism is quantification of signal in the globus pallidus from T1-weighted MR imaging of
the manganese that has accumulated in that region of the brain (Criswell, et al., 2012; Kenangil,
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et al., 2006; Josephs, et al., 2005). In our biodistribution results (Chapter 3), we observe uptake
of radiomanganese in the brain following intravenous administration of 52Mn.

1.2.3. Manganese-Based Contrast Agents for Magnetic Resonance Imaging
An additional motivation for understanding the biodistribution of free manganese is that
manganese(II) has been utilized in contrast agents for MR imaging. Manganese(II) is “high-spin”
from its five unpaired valence electrons (Wolf, et al., 1985; Weinmann, et al., 1984), which
shorten the spin-lattice time constant (T1) for nearby 1H nuclei, resulting in brighter signal when
using a T1-weighted MR pulse sequence (Pan, et al., 2010; Rodriguez-Vargas, 2010; Silva and
Bock, 2008), especially in anatomical regions with high water density. Gadolinium(III), by far
the most commonly used cation in clinically approved T1 contrast agents (Kahakachchi and
Moore, 2010; Rodriguez-Vargas, 2010; Caravan, et al., 1999; Lauffer, 1987) requires higher
coordination than Mn(II), giving Mn(II) better exchange kinetics with water molecules.
However, Gd(III) has seven unpaired valence electrons, imparting Gd(III) with greater T1
relaxivity (R1=1/T1) than Mn(II) in several different metal chelators.
The intravenous acute toxicity of Mn(II) chloride is similar to that of Gd(III) chloride
(LD50=0.3-0.5 mmol/kg in rodent models (Sigma-Aldrich, 2014; Bousquet, et al., 1988;
Weinmann, et al., 1984)), but manganese ions are nevertheless interesting for certain MR
applications, including utilizing the redox chemistry of chelated Mn(II/III) as an activatable
probe of the redox environment in tissue (Boros, et al., 2015; Gale, et al., 2014; Loving, et al.,
2013). Additionally, Mn complexes could serve as a safe alternative to Gd(III) (Brismar, et al.,
2012; Thomsen, 2009; Mendonca-Dias, et al., 1983), which might pose a health risk to patients
with renal insufficiency if Gd(III) dissociates from its chelator in the body (Pierre, et al., 2014;

7

Brismar, et al., 2012; Janus, et al., 2010; Ledneva, et al., 2009; Thomsen, 2009), since free
Gd(III) is excreted through the kidneys, but free Mn(II) is excreted through the liver (MendoncaDias, et al., 1983).
For these reasons, various complexes of Mn(II) (Zhu, et al., 2014) and Mn(III) (Cheng, et
al., 2014; Pierre, et al., 2014; Qazi, et al., 2014) are being developed, numerous kinds of Mndoped inorganic and organic nanoparticles are in the in vitro and pre-clinical stages (Pan, et al.,
2010, 2009, 2008), and oral administration of liquids containing Mn(II) has been tested in
humans (Brismar, et al., 2012; Hiraishi, et al., 1995). So far, the only manganese-based MR
contrast agent to reach the market in the United States was Teslascan® (mangafodipir;
manganese(II)-dipyridoxyl diphosphate (Mn-DPDP); Amersham plc, Amersham, United
Kingdom), which was used for detecting colorectal metastases in the liver (Elizondo, et al., 1991;
Rocklage, et al., 1989), and was withdrawn in the United States in 2003 because of low demand
(not safety concerns). Since MRI is not inherently as quantitative as PET, and since MEMRI is
not as widely studied as Gd-based imaging, it would be useful to “authentically” radiolabel
manganese-based MR contrast agents with radiomanganese (Coenen, et al., 2014; Klein, et al.,
2005) for quantitative confirmation of their biodistribution—by dissection, autoradiography,
and/or in vivo imaging.

1.3. Radioactive Decay, Detection, and In Vivo Imaging
Quantifying radiotracers is very sensitive and precise, and offers opportunities for in vivo
imaging. At least twenty-seven isotopes of manganese have been discovered, one of which is
stable. The twenty-six remaining isotopes decay by numerous different modes of radioactive
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decay, resulting in many different types of particle and energy emissions. Based on techniques
for detection and imaging and on half-lives that are useful for biomedical experiments, there are
only a few radioisotopes that are potentially valuable for biomedical applications, and, for the
majority of this dissertation, we will focus on cyclotron production and biomedical applications
52

Mn in particular.

1.3.1. Nuclear Decay and Radiation
There are many different modes of nuclear decay, all of which basically involve a
radioactive isotope seeking a more stable, less energetic state. Nuclear decay typically results in
the radioactive parent isotope releasing energy as particles (including positrons), gamma-rays, or
in other forms, as the nucleus transforms into a daughter isotope or isomer (which itself may be
stable or radioactive). Numerous types of radiation can be emitted—directly or indirectly—by
nuclear decay, and some of the most common kinds are summarized in Table 1.1.

Table 1.1. Summary of radiation emitted directly or indirectly by radioactive decay.
Type of Radiation

Charge

Mass

α

+2

β- or e-

-1

4.00
u
5.5e-4
u

Photon: from γ decay

None

0

Photon: from β+ annihilation
Photon: X-ray from e- capture

Primary Interaction(s) with
Matter Following Scattering
off Orbital Electrons
Ionization (sometimes
producing Cherenkov light)
Ionization (sometimes
producing Cherenkov light)
Bremsstrahlung radiation
Pair production (>1.02 MeV)
Compton effect
Photoelectric (<500 keV)
Photoelectric effect
Photoelectric effect

(Sources: ICSU/CODATA; Royal Society of Chemistry/Radiochemical Methods Group.)
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1.3.2. Non-Imaging and Ex Vivo Options for Detecting Radiation in
Biomedical Research
Although this dissertation focuses the application of a radioisotope of manganese for in
vivo imaging, it is important to consider alternative techniques that could also study the behavior
of manganese by detecting radiomanganese. This section discusses a few common non-imaging
techniques that are used for detecting radiation in medical radiochemistry.
Ionization is a mechanism of interaction between radiation and matter that is commonly
used for detecting and measuring radiation. Ionization of an atom occurs when the energy of the
radiation—particles, X-rays, or gamma-rays—is greater than the energy required to remove an
electron from an atom (different for 1st, 2nd, 3rd, etc. electrons of an atom). Following ionization,
in a detector, the resulting free electrons are attracted to an anode, and the cations to a cathode,
and the resulting current is measured by an electrometer circuit and is correlated to the ionizing
radiation that was originally detected. Gases are commonly used as the ionization medium
because of faster movement to the electrodes. The incident radiation that is best measured by
ionization is usually gamma-rays, beta particles, and annihilation photons.
Detectors that operate on this principle are classified as gaseous ionization detectors
Typically gaseous ionization detectors (dose calibrators) cannot measure the energy of radiation,
so accurately converting radiation into units of radioactivity requires the sample to only emit
radiation from one radioisotope that is known, as well as calibrating the device itself (Appendix
A) or by calculations.
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Figure 1.1. Illustration of the mechanism behind ionization chambers.
(Image courtesy of EQUIPCO. Used with permission.)

Gamma-ray energy can be measured by scintillation detectors and semiconductor
detectors. The most common type of scintillation detector uses a NaI crystal that has been doped
with Tl, and this crystal produces a small amount of visible light when it encounters a photon
with sufficient energy. The crystal is attached to the window of a photomultiplier tube (PMT),
which detects the light in the crystal, converts it to an electrical pulse, and amplifies this pulse
until it is large enough to be counted by the electronics connected to this system (Figure 1.2).
The brightness of the light in the crystal and the pulse height in the PMT are correlated to the
energy of the incident photon, so this energy can be estimated. A NaI(Tl) detector is used in
many gamma counters, including the ones that we used for quantifying radioactivity in our ex
vivo biodistribution experiments (Chapter 3), and this kind of detector was also used in the
radiation detector used in the radiation detector attached to our high-pressure liquid
chromatography (radio-HPLC) system.
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1. Introduction
Semiconductor nuclear radiation detectors have experienced a rather rapid development in the last
few decades. A major characteristic of this type of detector is the capability of converting γ-rays
directly into electronic signals. In comparison to scintillators, semiconductor detectors avoid the
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Figure 1. Planar configuration of a semiconductor detector. The cathode is applied with a
negative voltage and anode grounded. Electron-hole pairs excited by gamma rays are swept
by the bias voltage.

Figure 1.3. Illustration of the mechanism underlying semiconductor radiation detectors.
(Image from Q. Zhang, et al., 2013. Creative Commons.)
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Finally, autoradiography presents a method for two-dimensional mapping of the
distribution of radioactivity. This technique is best applied to mapping radioactivity in a planar
region, such as in a thin layer chromatography (TLC) plate, thinly sectioned ex vivo tissues, or
other applications. One common method for autoradiography utilizes a storage phosphor screen,
which consists of a layer of microparticles of BaFBr doped with Eu2+. Incident radiation of
sufficient energy will excite electrons in Eu2+ to a highly mobile state, causing Eu2+ to oxidize to
Eu3+, and BaFBr to be reduced to BaFBr-. These new states are maintained for up to a few weeks
until the screen is read in a scanner that excites the screen with 635 nm light and, using a bandpass filter, measured the blue light emitted by the screen at wavelengths surrounding ~390 nm.
The intensity of this light at each spot on the screen is proportional to the radioactivity originally
detected by the screen at that location, and this signal can be mapped in the control software to
form images. For anatomical imaging corresponding to the autoradiography, the tissue sections
are imaged in bright field by photography. Autoradiography presents a useful option for mapping
distribution of radioactivity that emits various types and energies of radiation, including gammarays and charged particles. Table 1.2 summarizes the different mechanisms and instruments that
were discussed that could be used to detect and quantify radiomanganese in experiments that do
not require in vivo nuclear emission imaging.
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Table 1.2. Summary of non-imaging technologies for detecting radioactivity.
Typical Particles
Detecteda

Examples of Applications

Gaseous Ionization Detectors
Ionization chamber

γ

Dose calibrator, survey meters

Scintillation counter

γ

NaI(Tl) gamma spectroscopy, gamma counter,
detector for radio-HPLC

Semiconductor detector

γ

HPGe detector

Storage phosphor screen

α,β,γ,n

Autoradiography for radioTLC plates, sectioned tissues,
whole body autoradiography of sliced small animals

a

Detection of positrons is not listed specifically in this table, but the 511 keV annihilation photons
can be detected by any detector that is capable of detecting gamma-rays with energy of 511 keV.

1.3.3. Techniques for In Vivo Imaging of Emitted Radiation
Despite the useful characteristics of these detectors, our goal was to perform in vivo
nuclear emission imaging. In general, for in vivo imaging applications, the best emissions are
photons that have either a low energy of or a specific known energy, specifically 511 keV
photons that result when a positron is emitted then annihilates with a nearby electron (Section
1.3.3.2). Photons with energy 30-250 keV (Peterson and Furenlid, 2011) have an energy that is
great enough that, on average, they are not completely attenuated within a body, but low enough
to be useful for imaging modalities based on gamma cameras (i.e., planar scintigraphy and
SPECT). The 511 keV photons are useful for PET imaging, which uses a filter that will only
count photons with an energy surrounding 511 keV (~350-650 keV (Phelps, et al., 2006)). This
ability to resolve the energy of photons and then select signal from photons in a specific energy
range enables rejection of counts from photons that originated from another location and have
lost energy from significant scattering, thereby increasing the signal-to-noise ratio (SNR) in the
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imaging. These factors are important to consider when selecting radioisotopes for experiments
because of the different kinds of radiation required for different nuclear imaging modalities.

1.3.3.1. Non-PET Nuclear Emission In Vivo Imaging Modalities
For isotopes that emit photons in the 30-250 keV window, gamma cameras present a very
useful technology for detecting radiation to produce signals that can be reconstructed into
images. Gamma cameras, also known as an Anger camera after its inventor, operate on similar
principles as scintillation counters (Section 1.3.2) and in some ways are simply an array of these
counters that are used to produce two-dimensional maps of radiation emitted from the imaging
subject. Gamma cameras are the detectors behind the modalities of conventional nuclear
medicine: planar scintigraphy and single photon emission computed tomography (SPECT).

1.3.3.2. Positron Emission Tomography
The positron emission mode of nuclear decay is of particular importance in medical
imaging. In a typical medium, positrons will scatter inelastically off orbital electrons, causing
ionization of atoms, over a range of only a few millimeters before annihilating with an electron.
This annihilation converts the mass of the positron and the electron into two photons that are
released at 511 keV each in directions that are almost exactly 180° from each other due to
conservation of momentum. The physics of positron annihilation, particularly the specific
direction and energy of the annihilation photons, form the basis of positron emission tomography
(PET), which is an imaging modality in clinical nuclear medicine.
PET has important advantages over the more traditional nuclear medicine modalities
based on its underlying physics. PET is optimized to only image the distribution of annihilation
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events from positrons, which gives PET high specificity in terms of signal. This signal specificity
relies on a few special aspects of positron emission and annihilation:

(1) Positrons in tissue have a short range before annihilation.
(2) The photons emitted from annihilation are always ~180° in opposite
directions.
(3) The annihilation photons always have energy of 511 keV.
(4) Both photons, travelling through different amounts of tissue and air, have high
enough velocities that they will reach a ring of detectors quickly and with very
little difference in time of arrival (i.e., in coincidence).

These characteristics mean that determining the concentration of annihilation events is related to
the concentration of parent nuclei. Furthermore, the location of annihilation events in each slice
can be detected by a ring of detectors that only count photons with energy in a range surrounding
511 keV and only when another photon is detected in a detector located ~180° away within a
very short time window (on the order of nanoseconds). The mechanism of PET is illustrated in
Figure 1.4.
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Figure 1.4. Illustration of the physics of positron emission tomography.
(Image: van der Veldt, et al., 2013. Creative Commons.)

After detecting coincident photons that meet these criteria, the PET system can define a
line of response (LOR) for those two photons. As the number of counts of coincident photons
increase during a scan the many LORs that are created begin to intersect in regions with the
highest density of annihilation events during the scan time, which closely describes areas that
had high concentration of positron emitting nuclei during the scan. This information can be
acquired as two-dimensional regions if only a single ring of detectors is used for each image
slice, or as three-dimensional regions if multiple rings are used. At this point, various signal
processing algorithms can be applied to improve the image that will result from image
reconstruction. The image slices are reconstructed into a three-dimensional tomograph that
reflects the distribution of a PET radiotracer in vivo.
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Figure 1.5. Photograph of a General Electric (GE) Optima PET/CT 560 human scanner.
(Image courtesy of GE Healthcare. Used and adapted with permission.)

Detailed anatomical imaging is provided by computed tomography (CT) or magnetic
resonance imaging (MRI) and is frequently co-registered with a PET image in multimodality
techniques known as PET/CT or PET/MR, respectively. When two-dimensional presentation is
desired, the co-registered tomographs are often converted to a maximum intensity projection
(MIP) in the direction of a selected point of view. Figure 1.6 shows examples for PET, CT, and
MR images (with fusion) from a 62 year-old woman with multiple myeloma (Fowler, et al.,
2013). Signal from PET clearly shows a lesion in the region of the left shoulder that was avid for
[18F]-fluorodeoxyglucose (18F-FDG), which is a simple analog for glucose that has been
radiolabelled with the positron-emitting radionuclide
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F.
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F-FDG is currently the most

commonly used radiotracer for PET worldwide, and it can detect regions of high glucose
consumption, such as tumors that demonstrate sufficient contrast in PET imaging by not being
near areas of naturally high signal, especially the brain and bladder.
The physics of PET translates into advantages for this modality, including extremely high
sensitivity because all radiation is rejected except for that which has a specific energy,
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SIMULTANEOUS PET/MRI ACQUISITION
Clinical cases
The following are some examples of
the clinically relevant cases acquired for
anatomically focused and whole-body
examinations with the Biograph mMR.

directionality, and coincidence timing. The sensitivity of PET is on the order of picomolar

Neuro-oncologic brain imaging
While separately
acquired brain MR
concentration of radiotracer, and better sensitivity means that much less totaland
mass
of a contrast
FDG-PET images can be fused
through various software tools, a com-

bined examination
permits streamlined
agent needs to be administered, which can decrease concerns for chemical toxicity
and radiation

patient care and improves diagnostic
specificity. The convenience and reduced burden
to the patienttoof a single
dosimetry in patients. Although nuclear imaging in general has poor resolution
compared
imaging session is particularly relevant
to patients with brain tumors, who often
have a reduced
functional
status.
other medical imaging modalities such as CT or MRI, PET generally boasts
better
spatial
Figure 1 displays a panel of selected
simultaneous FDG-PET/MR images of
a 41-year-old man with a left temporal
resolution than SPECT.
lobe primitive neuroectodermal tumor
FIGURE 3. Buccal cancer. Images depict a metabolically active tumor in the right buccal
space (arrows), which also is well shown on the DWI and ADC map to restrict diffusion. The
(PNET) treated with near-total resecpatient had biopsy-proven metastatic involvement of Ib lymph nodes within the right submantion, craniospinal and resection-bed
dibular space (open arrows).
radiation therapy, and adjuvant chemotherapy. Follow-up MRI showed a
growing, enhancing mass, and FDGPET/MRI was performed to differentiate recurrent tumor from radiation
necrosis. The white arrow denotes an
enhancing nodule with markedly increased FDG uptake, highly suspicious
for recurrent PNET. Subsequent surgical resection demonstrated a mixture of
recurrent PNET and radiation necrosis.

Amyloid PET brain imaging
The development of F-18-labeled
PET tracers for imaging beta-amyloid
plaques that occur in Alzheimer’s disease (AD) has the potential to increase
the certainty of diagnosis in patients
with cognitive impairment. One of
these tracers, F-18 florbetapir, recently
received FDA approval for clinical use,
and several other amyloid PET tracers
in late-phase clinical trials may soon
become clinically available. If drugs
that slow or reverse the development of
AD dementia become clinically available, amyloid PET imaging may be a
key component of patient selection for
treatment and for monitoring response
to therapy. The anatomic, volumetric,
FIGURE
4. Multiple
myeloma.
Images depict
a focus
of metabolically
activeCT,
disease
in the
Lesion
from
multiple
myeloma
viewed
with
FDG-PET,
and
MR.
left humeral neck that is more conspicuous on MRI than on CT alone (arrows).
and functional data available through

Figure 1.6.
Arrow: lesion; AC: attenuation correction; HASTE, STIR: pulse sequences for MRI. (Image:
Fowler, et al., 2013. Reprinted with permission of Anderson Publishing Ltd. From Fowler, K.;
2013
www.appliedradiology.com
APPLIED RADIOLOGY
McConathy, J.; June
Khanna,
G.; Dehdashti, F.; Benzinger,
T.L.S., et al., 2013. Simultaneous
PET/MRI acquisition: Clinical potential in anatomically focused and whole-body examinations,
Applied Radiology, pp. 9-14. ©Anderson Publishing Ltd.)
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1.4. Selection of 52Mn as a Radiotracer
A need exists for a tracer of manganese that is radioactive, detectable, and imageable,
specifically by PET, at timepoints of hours and days. The radioisotope that best satisfied our
criteria was 52Mn, which can be produced on-site at our medical center using cyclotrons from a
low-energy, biomedical cyclotron.

1.4.1. Selection Criteria for a Radioisotope of Manganese
Many different factors, including scientific, engineering, facilities, and cost reasons
contribute to the selection of a radioisotope for experiments. These considerations result from the
following factors related to the production of medical isotopes: capabilities and limitations of
radiation detection and imaging, decay properties and radiation emissions of radioisotopes,
requirements for nuclear reaction channels, and production costs associated primarily associated
with target materials and beam time for a cyclotron. This section discusses these selection
factors, which are also summarized in Table 1.3.
Based on the technologies discussed earlier (Sections 1.3.2-1.3.3), many different types
of emitted radiation can be useful for imaging and non-imaging applications. For both imaging
and non-imaging technologies, these different kinds of radiation can be detected directly or
indirectly. However, when selecting the radionuclide, it also must emit the desired radiation at a
sufficient total intensity (Itot), which is the total fraction of radionuclei that will emit a particular
radiation type, at a certain energy as a part of their decay to a daughter nuclide.
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Table 1.3. Selection considerations for radionuclides in biomedical experiments.
Criteria

Application

Typical Choice

Radiation emitted can be detected

Ionization/Proportional counter
Semiconductor
Phosphor screen
Scintillation: counter
Scintillation: scintigraphy/SPECT
Scintillation: PET

γ
γ
γ
γ
γ (Eγ~30-250 keV)
511 keV coincident photons
(from positron annihilation)

Nuclear half-life matched to
biological half-life

Small molecules
Peptides, antibody fragments
Intact antibodies, nanoparticles
Long-term biodistribution

Minutes-Hours
Hours
Days
Months

Production routes

Generator (from nuclear reactor)
Low-energy cyclotron
High-energy ion accelerator
Nuclear reactor

It is also important to consider the timescale of the experiment that will be utilizing the
radiotracer. Most benchtop chemistry and in vivo experiments require isotopes with half-life for
nuclear decay (t1/2) of at least 1 minute for very quick experiments and less than 1 year for the
longer tracer experiments. In particular, radiolabelled compounds for in vivo experiments should
use radiolabels that correspond to the biological half-life of the targeting agent, meaning the time
from administration for one-half of the dose to either reach its target or to be excreted. These
targeting times can vary over a broad range, typically increasing with the size of the
radiolabelled compound: roughly minutes for small molecules, hours for peptides and antibody
fragments, and days for nanoparticles and intact antibodies. It is essential to select a radiolabel
with a half-life that is long enough for sufficient radioactivity to remain at the desired timepoints
post-administration for detection or imaging. In vivo imaging studies require more emission
signal than simple counting and spectroscopy experiments, so the half-life of an imaging
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radioisotope should also be short enough to provide a sufficient rate of nuclear decay to produce
enough counts in a reasonable scan time.
A final major consideration for radioisotope selection is the cost and ease of acquisition
or in-house production. Many radioisotopes with sufficient market demand are available
commercially, including numerous long-lived radiotracers and several isotopes for SPECT and
PET, even the non-traditional PET isotopes 64Cu, 89Zr, and 124I. Certain government laboratories
and universities are capable of producing a variety of radioisotopes from large instruments, such
as nuclear reactors, linear accelerators, ion beams, and spallation targets. These instruments are
necessary for isotope production via certain nuclear reaction channels that require different
incident particles and/or higher incident energies, and these facilities supply commercial vendors
with large batches of parent isotopes for generators, alpha- and beta-emitting radioisotopes for
therapy, and certain SPECT isotopes.
However, the vast majority of production of PET isotopes is performed by proton
bombardment from a low-energy cyclotron located on-site at academic or commercial medical
centers. The cost of target material can be reduced by selecting isotope products and reaction
channels that require target nuclei with high natural abundance. Due to the costs charged for
isotopically enriched materials, even slight enrichment of the most abundant metals can cost
more than naturally monoisotopic metals. Recovery and recycling of target material for future
productions, which can be a time consuming process can also help keep costs down. A good
example of a cost-efficient cyclotron target is production of the PET isotope 89Zr by the 89Y(p,n)
reaction. Natural yttrium is monoisotopic (as 89Y), affordable, and, therefore, the dissolved target
material does not necessitate recovery from its chemical processing and can simple be disposed
as waste.
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1.4.2. Potentially Useful Radioisotopes of Manganese
There are several radioisotopes of manganese that satisfy broad criteria for being useful
for radiochemistry experiments, and a smaller number satisfy practicality criteria for half-life and
production. Nuclear decay properties for several of these potentially useful radioisotopes of
manganese are summarized in Table 1.4. The radioisotope

54

Mn emits positrons and beta

particles that might be useful for various applications, but the intensities are Iβ+=5.8×10-7% and
Iβ-=2.9×10-4%, which are much too low to be practically useful. However,

54

Mn also emits a

gamma-ray at an energy (Eγ=835 keV) that is not suitable for in vivo imaging but very feasible
for several non-imaging detection methods, and the intensity of this gamma-ray is more than
sufficient (Iβ+=99.98%). Many other radioisotopes of manganese emit radiation that meets the
criteria described above, yet only a few of these radioisotopes satisfy the half-life requirements
for most radiolabelling and in vivo experiments. The radioisotopes

46-52,46m,50m,52m,54

Mn all emit

positrons, and the intensities exceed, to varying degrees, the intensities of several other PET
radiometals: Iβ+>99% for 46-50Mn, Iβ+>95% for 51,52mMn, and Iβ+=29.6% for 52Mn. However, only
positron emitters

50m,51,52,52m

Mn have nuclear half-lives that are in the realistic range to be of

practical use in terms of half-life of nuclear decay.
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Table 1.4. Comparison of decay properties of radioisotopes of manganese.
Applications
Long-lived gamma-emitter
PET

Candidate Isotopes
54
Mn
46-50

Mn
Mn
51
Mn
52m
Mn
52
Mn
50m

SPECT
Radiotherapy

Half-Lifea
312 days

Pertinent Emissiona
834.8 keV (99.98%)

<0.5 sec
1.8 min
46.2 min
21.1 min
5.6 days

Various (≥99%)
1.54 MeV (106%)
963 keV (97.1%)
1.17 MeV (95.0%)
242 keV (29.6%)

None
56

Mn

2.6 hours

833 keV (99.9%)

Percentages reflect total intensities for each type of emission. (Data accessed via:
a
BNL/NNDC/ENSDF.)

Only

52

Mn satisfied our preferences for a positron-emitting radioisotope of manganese

with a relatively long half-life, so we selected 52Mn as the radiotracer for manganese behavior in
our experiments. This isotope had the additional benefit that it can be produced in-house by
proton bombardment from a low-energy cyclotron, instead of requiring a large-scale ion
accelerator or a nuclear reactor.

1.4.3. Characteristics of 52Mn
Manganese-52 is unique in its half-life of several days which, was ideal for our
applications. The total intensity and average energy of positron emission makes

52

Mn a strong

candidate for PET imaging; the abundance of gamma-rays make it a good candidate for nonimaging radiotracer experiments where a detector for gamma-rays is used. Figure 1.7 and Table
1.5 show simplified decay data for 52,52mMn.
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Figure 1.7. Simplified level decay scheme for 52,52mMn.
Only showing emissions with Itot>1%. (Data accessed via BNL/NNDC/ENSDF.)

Table 1.5. Data for radioactive decay of 52Mn.

(Data accessed via BNL/NNDC/ENSDF.)
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1.4.4. Comparison of 52Mn to Other PET Isotopes
Our primary motivation for using 52Mn for PET imaging is to study the interesting in vivo
behavior of manganese and manganese-labeled compounds. The radioactive decay
characteristics of 52Mn as compared to other PET isotopes is provided in Table 1.6.

Table 1.6. Comparison of decay characteristics of 52Mn to other PET radionuclides.
Half-Lifea
52

Mn
I
89
Zr
86
Y
64
Cu
18
F
68
Ga
11
C
124

5.6 d
4.2 d
3.3 d
14.7 h
12.7 h
110 m
68 m
20 m

Positron Emission
Weighted Average Energya Total Intensitya
(keV)
242
29.6%
820
22.7%
396
22.7%
660
31.9%
278
17.6%
250
96.7%
830
88.9%
386
99.8%

Gamma Radiation
Gamma Factorb
(R·cm2·mCi-1·h-1)
18.4
6.6
6.6
18.9
1.1
5.7
5.4
5.9

(aData accessed via BNL/NNDC/ENSDF. bData from: Smith and Stabin, 2012.)

In terms of acquiring the radionuclide needed for a PET study, Table 1.7 compares the
routes for producing the PET isotopes that were listed in Table 1.6.

Table 1.7. Comparison of 52Mn to other PET radionuclides.

52

Mn
I
89
Zr
86
Y
64
Cu
18
F
68
Ga
11
C
124

Production
Most Common Target Target Natural Abundancea
52
Cr(p,n) (Solid)
83.8%
124
Te(p,n) (Solid)
4.7%
nat
Y(p,n) (Solid)
100.0%
86
Sr(p,n) (Solid)
9.9%
64
Ni(p,n) (Solid)
0.9%
18
O(p,n) (Liquid)
0.2%
68
Ge (Generator)
14
N(p,α) (Gas)
99.6%

(aData accessed via: BNL/NNDC/ENSDF.)

26

In summary, the

52

Cr(p,n) reaction provides a route for producing

52

Mn, an imageable

radiotracer with a half-life of several days, for experiments that depend on the chemistry of
manganese.

1.5. Thesis and Scope of this Dissertation
The thesis for this dissertation is: Manganese-52 (52Mn) is feasible to produce using a
biomedical cyclotron and simple chemical isolation that can be automated, and

52

Mn can be a

useful PET radioisotope for detecting and imaging the chemical and biological behavior of
Mn(II) cations, salts, and radiolabelled compounds. The scope for this dissertation can best be
grouped into four categories that are reflected in the chapters herein:

•

Nuclear cross-sections and chemical separation (Chapter 2)

•

Biodistribution and PET imaging of 52Mn (Chapter 3)

•

Applications of 52Mn in PET/MR imaging (Chapter 4)

•

Remotely-controlled modules for the isolation of PET radiometals (Chapter 5)
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Chapter 2. Nuclear Cross-Sections and
Chemical Separation of 52Mn1,2,3,4
2.1. Background
Essential to any routine isotope production protocol is the ability to select target
thickness, beam energy, beam current, and bombardment time based on predicted yield, which in
turn is based on nuclear cross-section data. Nuclear cross-sections are a means of expressing the
probability of a nuclear reaction channel occurring when matter is bombarded with ions,
neutrons, etc. It is expressed as the effective cross-sectional area of the target nuclei, hence its
name and dimensions of length squared. Cross-section is often expressed as cm2 or barns,
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although millibarns are more appropriate for many reaction channels that are induced by lowenergy protons, such as those from the cyclotrons at our institution.
Target thickness and beam energy are typically selected so that the entry and exit
energies of the beam will span a region of the excitation function with high cross-sections for the
product and little or no cross-sections for other, competing reaction channels that may produce
contaminant isotopes. Designing production runs to optimize this energy “window” can improve
yield and radionuclidic purity of the final product. Thus, it is important to have accurate crosssection data for not only the reactions that produce the desired product, but also for the reactions
that would produce contaminant isotopes. In this investigation, we bombarded chromium targets
of natural isotopic abundance (natCr =

50

Cr (4.3%),

52

Cr (83.8%),

53

Cr (9.5%),

54

Cr (2.4%)),

which could potentially produce several product isotopes. This work focused primarily on
measurements for the production of

52

Mn, but also for

52m

Mn and

54

Mn as radiocontaminants.

Only a few data sets are currently available with points at proton beam energy (Ep) ≤14 MeV for
the

nat

Cr(p,x) reactions that produce

52,52m

Mn (Buchholz, et al., 2013; West Jr, et al., 1987;

Barrandon, et al., 1975), and there are only data sets from enriched targets available for 54Mn at
these low energies (Levkovskij, 1991; Gusev, et al., 1990; Skakun, et al., 1986; Zyskind, et al.,
1978; Kailas, et al., 1975; Johnson, et al., 1960). In this work, we contribute new experimental
cross-section data for each of these (p,x) reactions that produce 52,52m,54Mn from bombardment of
natural chromium with protons at low-energies.
The excitation peak for the 52Cr(p,n)52Mn reaction is in the 24à6 MeV range of proton
energies, meaning that production is optimized with ~24 MeV incident protons bombarding a
target containing 52Cr that is thick enough to degrade the proton energy all the way to ~6 MeV
(threshold for the 52Cr(p,n)52Mn reaction: Ep = 5.6 MeV). This is also the optimal energy range
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for producing the metastable isomer 52mMn, which has an excitation function ~2-3x greater than
the ground state. However, this short-lived radiocontaminant (t1/2=21.1 min.) is practically
eliminated by decay within hours, without contributing significantly to production of the ground
state because 52mMn has a branching ratio of <2% for isomeric transition to 52Mn.

2.2. Experimental
2.2.1. Materials
Copper sheet (0.762 mm thick, 99.9% purity) was purchased from ESPI Metals (Ashland,
Oregon, United States), and copper foil (0.025 mm, 99.999% purity) was purchased from Alfa
Aesar (Ward Hill, Massachusetts, United States). Natural abundance chromium was
electroplated by Four Star Finishing (Saint Louis). The aluminum for the target holders were
6061-T6 aluminum alloy, pure aluminum (A.D. MACKAY, Denver North Carolina, United
States), or pure niobium metal (A.D. MACKAY). All other solid and liquid chemicals were
purchased from Sigma-Aldrich (Saint Louis, Missouri, United States), unless otherwise
indicated. Nitrogen (N2) gas was purchased from Cee Kay Supply (Saint Louis).

2.2.2. Target Preparation
Copper monitor foils were produced by punching ~9.5 mm discs from 0.762 mm
(nominal) copper foil. However, Cr metal is very brittle, so cutting or punching discs from thin
Cr foil was not feasible. Furthermore, thin Cr foil was not commercially available without a
permanently attached Mylar (polyethylene terephthalate) backing.
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Therefore, we developed a method for fabricating batches of thin Cr foils that would fit
into target holders. Thin, circular foil discs were produced through a process of electrodeposition
of non-enriched Cr onto small plugs of Cu backing material, followed by removal of the Cu
backing, similar to a method used in the past (Tanaka and Furukawa, 1959). Holes (~10 mm
diameter) were cut or punched from Cu sheet, and these holes were then filled using ~9.8 mm Cu
discs that were punched from elsewhere on the Cu sheet. On the “back” side of the plate, these
discs were fixed in place by soldering the back of each disc to one of several long strips of thick
(~1-2 mm diameter) bus bar wire that was also soldered to the large copper plate. Figure 2.1
shows a sample that contained a 13x13 grid of copper plugs soldered in place on the back.
The back of the sample was masked with a lacquer, and the entire sample was submerged
(while connected to the cathode) into an industrial-scale chrome plating bath, and the unmasked
side of the sample was electroplated with Cr. This bath electroplated with “hard chrome,”
meaning thick (tens to hundreds of µm), ultra hard deposits of pure Cr metal. (The more popular
type of chrome plating, “decorative chrome”, is roughly 1,000x thinner and usually plated over
nickel or copper.) The bath was an aqueous solution of 100:1 chromic acid (H2CrO4) and sulfuric
acid (H2SO4). (Safety note: The chromic acid was made from chromium(VI) oxide (CrO3
powder), which is acutely toxic (Sigma-Aldrich, 2014).) The sulfuric acid was a commonly used
additive that contributed sulfate groups to the solution, which catalyzed the electroplating
reaction (Mandich and Snyder, 2010). To produce individual Cr discs, the bus bar wire was
clipped on either side of each copper plug in the assembly, producing individual copper plugs
plated on one side with chromium. These plugs were placed in ~3-8 M nitric acid in a large glass
container. The nitric acid digested the copper while leaving the chromium intact, and the acid
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solution was changed several times during this process. The final result was circular discs of thin
(and very brittle) Cr metal foils with a diameter of 9.8 mm.

Figure 2.1. Photographs illustrating the process for the fabrication of thin Cr foil discs.
These images are representative images and not from the same production. (A similar figure was
published in Wooten, et al., 2015 (supplementary information). Image courtesy of Elsevier. Used
with permission.)

Before each stack of foils was assembled, the thickness of each Cr and Cu foil was
calculated based on its diameter and mass, assuming cylindrical geometry. Based on instrumental
uncertainty from the measurements of diameter and mass, the uncertainty in the calculated
thickness of each Cu or Cr foil was <1.1%. Across all the Cr foil discs in all configurations and
bombardments the diameter was 9.8 mm for all discs, with an average thickness of 82 µm
(±10.5%), and the Cu foil discs had a diameter of 9.5 mm and an average thickness of 18.6 µm
(±2.6%).
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Cr foils were tested for elemental purity by a sixty-element screening performed by
Galbraith Laboratories (Knoxville, Tennessee, United States). The foil was dissolved in acid and
analyzed by inductively coupled plasma mass spectrometry (ICP-MS). The only contaminants
>100 ppm (within uncertainty) were Sn (1195 ppm) and Se (134 ppm). This was a semiquantitative screening with relative error of up to 50% for all measurements.
A custom target holder was designed and machined out of 6061-T6 aluminum alloy
(95.8-98.6% aluminum) to hold the stacks of foils during cyclotron bombardment. Our design
consisted of a base containing a dish with smooth vertical walls to hold the stack of foils yet
allow for quick, easy removal of the foils from the dish after bombardment. The base had a blind
hole on the non-vacuum side for improved contact with the circulating cooling water. The target
holder also included a screw-on cap to hold the stack of foils in the holder when the foils were
held vertically in the target station—perpendicular to the incident beam. This cap was threaded
to match corresponding threads on the base, and the cap had a circular “window” to expose the
foils directly to the beam.

Figure 2.2. Photograph of one style of target holder used in this dissertation.
(The photographs on the left and right sides of the arrow are representative images, since they are
not pictures of the exact same components or even the exact same designs.)

Four different stacked foil configurations consisting of Cu and Cr foils were used in this
work to measure cross-sections in the Cr foils. The Cu foils were included for determination of
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flux (Section 2.2.4.5) and entry energy (Section 2.2.4.4) of the proton beam based on monitor
reactions in the Cu. Each configuration was bombarded in three separate targets, for a total of 12
bombarded targets in this work. The energy of the proton beam at the middle of every chromium
foil was predicted using The Stopping Range of Ions in Matter (SRIM) software (Ziegler, et al.,
2010), which implements the perturbative Bethe formula (with Bloch correction) for the stopping
power (i.e., energy loss) of charged particles due to interactions with orbital electrons in a
material.

2.2.3. Cyclotron Bombardment
Each target assembly was bombarded with low-energy (Ep<15 MeV) protons from the
CS-15 cyclotron (The Cyclotron Corporation, Berkeley, California, United States) at the
Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine
(WUSM). During bombardment, the back of the target holder was cooled by circulating chilled
water (T≈2-5 °C), and the front of the target was cooled by a He gas jet. Bombardments used in
this work were typically 1-3 µA for a duration of bombardment (tb) that varied between 105 and
135 sec, (120±15 sec). This uncertainty was accounted for (Section 2.2.4.8) in our determination
of beam energy, beam current, cross-sections, and saturation yields.

2.2.4. Cross-Section Measurement
2.2.4.1. Gamma-Ray Spectroscopy
Proton bombardment of the stacked foil targets produced radioisotopes in each Cu and Cr
foil, and these product isotopes were identified and quantified by gamma-ray spectroscopy from
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a high-purity germanium (HPGe) detector (model: GC2018; relative efficiency: 24.5%) that was
connected to a digital spectrum analyzer (DSA; model: DSA-1000) and operated by the Gamma
Acquisition & Analysis module of the Genie 2000 spectroscopy software package (v. 3.3). All
three components were from Canberra (Meriden, Connecticut, United States). The principal
isotopes measured were 63,65Zn in the Cu foils and 52,52m,54Mn in the Cr foils, and their production
and decay characteristics are summarized in Table 2.1.
A few hours after each bombardment, the stacked foil target was carefully disassembled.
For each gamma-ray counting experiment, one foil was placed in a small weigh boat that was
then placed on a 3 mm thick plastic shelf positioned at one of several distances directly above the
open end of the HPGe crystal. Various positions were utilized so that samples could be counted
at different distances from the detector to ensure a detector dead time (td) that was ≤5% of
detector real time (tr). Each Cu and Cr foil was counted for at least 10 min. of detector live time
(tl). Additionally, all of the Cu foils were counted again several months later for 10 h each to
measure a greater number of counts from the long-lived product
statistics.
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65

Zn (t1/2=244 days) for better

Table 2.1. Summary of the radioisotope products in irradiated Cu and Cr foils.
Primary Target†
(Natural Abundance)
63
65

Cu foil:
Cu (69.2%)
Cu (30.9%)

52

52

Cr foil:
Cr (83.8%)

Cr (83.8%)

54

Cr (2.4%)

63

Product
(Half-Life)

Gamma-Rays‡
(Branching Ratio)

Zn (38.5 min.)

670 keV (8.2%)
962 keV (6.5%)
1116 keV (50.0%)

63

Cu (stable)

65

Cu (stable)

1434 keV (100%)
936 keV (94.5%)
744 keV (90.0%)
1334 keV (5.1%)
1246 keV (4.2%)
848 keV (3.3%)
1434 keV (98.3%)
378 keV (1.7%)
835 keV (99.98%)

52

65

52

52m

Zn (244 d)

Mn (5.6 d)

Mn (21.1 m)

54

Mn (312 d)

Daughter
(Half-Life)

Cr (stable)

52

Cr (stable)
Mn (5.6 d)
54
Cr (stable)

52

†

All of the product isotopes in this table are produced primarily by (p,n) reactions from proton
bombardment of Ep<15 MeV. ‡In our analysis, we only considered gamma-rays that were emitted
by only one isotope/isomer, so the 1434 keV gamma-rays emitted by both 52Mn and 52mMn was
excluded from analysis. (Nuclear data accessed via: BNL/NNDC/ENSDF.)

The HPGe detector was calibrated for photopeak energy and detector efficiency. The
energy calibration was performed using a mixed-gamma source in a sealed microcentrifuge tube
(Eckert & Ziegler Analytics, Atlanta, Georgia, United States). We also performed our own
detector efficiency calibrations using a mixed-gamma “point source” (Eckert & Ziegler
Analytics). The detector efficiency (εc) was calculated for each gamma-ray energy (Eγ), and ln εc
was plotted versus ln Eγ. This plot was linear between 166-1836 keV, so the data in this range
were fit to the equation:

ln !! = m ∙ ln !! + ! ,
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(2.1)

where m and b are the slope and intercept of the linear fit. All gamma-rays measured in this
investigation were within this range and are listed in Table 2.1. Equation 2.1 was solved for εc
and fitted by floating for m and b using the gnuplot software (v. 4.6.6) (Williams, 1986), which
implemented a non-linear least squares algorithm (Levenberg-Marquardt algorithm) (Crawford,
2014). The resulting fits served as calibration curves for calculating detector efficiencies for
gamma-rays emitted by radionuclide products in the irradiated Cu or Cr foils. This calibration
was performed for each geometry counting of irradiated Cu or Cr foils.
The fitting method weighted the fit parameters based on y-direction uncertainty in the
data points. This uncertainty represented the uncertainty of the gamma emission rates for each
gamma-ray from the calibration source (taken from the reference sheet), as well as the
uncertainty in the counting of these emissions (Section 2.2.4.8). To improve the goodness-of-fit
value, we would sometimes increase the level of statistical error to 1.5 or 2 standard deviations.
This improved the fitting, and the additional uncertainty was accounted for in the uncertainty of
the fitted parameters and propagated accordingly.
Additionally, to test for self-shielding in our Cr foils, we performed a calibration with the
point source positioned directly above the same type of Cr foil used in our stacked foil
experiments. The resulting efficiency calibration curve had a slope and y-intercept that were both
within 0.5% of the values in the efficiency curve that we used for foils that were counted from
the same geometry, thus illustrating that there was no significant attenuation of gamma rays by
the foils themselves.
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2.2.4.2. Data Analysis
We concur with Gagnon, et al. (2011a) that transparent, detailed explanation of analysis
in cross-section experiments can reduce confusion in comparing and categorizing these studies.
Here, we explain in detail the analysis that was used to transform counts from gamma
spectroscopy into activity, then beam energy, then beam current, and finally into cross-section
results for

52,52m,54

Mn. We also describe our uncertainty analysis. Unless otherwise stated, all

analysis work was performed in Excel for Mac 2011 (v. 14.4.4) (Microsoft, Redmond,
Washington, United States) or Excel 2002 (v. 10) (Microsoft) for Windows (Microsoft).

2.2.4.3. Calculating Radioactivities of Radionuclide Products
The principle raw data for this investigation came from gamma spectroscopy, specifically
the net peak area or number of counts (Nc) in each full-absorption photopeak of interest. For each
such peak, the activity of the corresponding radioisotope at the beginning of counting (Ac) was
proportional to the number of counts according to the following equation (Canberra, 2009):

!! = !

!!
! !! !! !!

,

(2.2)

where Iγ is the branching ratio for the gamma-ray, and Cd is the following correction factor for
decay during counting of the first member of a decay chain (Canberra, 2009; IEEE, 1999;
Moore, 1973):

!! =

!!! !!!!
!!!
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,

(2.3)

where λ is the decay constant for the isotope (λ=ln(2)/t1/2). For isotopes with multiple
characteristic gamma-rays, the activities (and uncertainties) calculated for the gamma-ray peaks
were combined to a single value by an inverse-variance weighted average. Then, each activity
was decay-corrected to the activity at EOB (AEOB).

2.2.4.4. Calculating Energy of Proton Beam
The entry beam energy was calculated based on monitor reactions (Gagnon, et al., 2011a;
Avila-Rodriguez, et al., 2008; Kim, et al., 2006; Takacs, et al., 1997; Blessing, et al., 1995;
Scholten, et al., 1994; Kopecky, et al., 1993; Piel, et al., 1992; Tarkanyi, et al., 1991; Kopecký,
1985). In this work, we used the

nat

Cu(p,x)63,65Zn monitor reactions with recommended cross-

section data provided by the Nuclear Data Section of the International Atomic Energy Agency
(IAEA/NDS). The activities were measured (Section 2.2.4.3) for 63Zn and 65Zn produced in a Cu
monitor foil on top of the stack in n=5 different targets, and the ratio of the activities, AZn-63 / AZn65,

was used to find the corresponding proton beam entry energy. This was determined by linear

interpolation between two adjacent points of the activity ratio calculated using the IAEArecommended cross-section data (increment=0.1 MeV) in the following equation (Gagnon, et al.,
2011a; 2011b; Avila-Rodriguez, et al., 2009):

!!"!!" !"#
!!"!!"!"#

!

= !!"!!"
!"!!"

!!! !!!"!!" !!
!!! !!!"!!" !!

,

(2.4)

where σ is the cross-section and tb=120±15 sec. Uncertainty was propagated through Equation
2.4 and through the linear interpolation.
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After determining the proton beam energy in those foils, the inverse-variance mean of
those energies was determined to be the beam energy at the midpoint of the Cu foil on top of the
stack (Ep=13.10±0.04 MeV) (Figure 2.3). The Transport of Ion in Matter (TRIM) module within
the SRIM software package was used to perform Monte Carlo simulations of transmitted ions to
determine that the entry energy was 13.285±0.065 MeV, thus this was used as the entry energy
for simulating the energy of the proton beam at the midpoint of all foils in all targets. Because of
the spread in the thickness of our Cr foils, the beam energies for all foils in all configurations
(excluding top Cu foils) were simulated using individual thicknesses that had been determined
by mass (Section 2.2.2). We excluded from the data set any Cr foils where the beam energy was
degraded >1.5 MeV from the midpoint of the previous foil to the midpoint of that Cr foil because
of the thickness of the foils and the energy of the beam. The longitudinal straggling of the
protons was estimated as the population standard deviation of the energies of N≈1,000
transmitted protons. We estimated that the uncertainty in the entry energy (±0.04 MeV) was not
correlated to the uncertainty in the beam energy in each foil in the stack, so we added this value
(in quadrature) to the uncertainty due to longitudinal straggling in each TRIM simulation. We
increased this uncertainty for the simulated beam energy at the midpoint of each foil by 1.1% to
estimate the effect of the uncertainty in the measured thickness of each Cu and Cr foil (Section
2.2.2).

47

Figure 2.3. Plot showing the activity ratios calculated using tb=120 sec and recommended
cross-section data from the IAEA for the natCu(p,x)63,65Zn monitor reactions.
A 6th-order polynomial fit to those results between 10-16 MeV proton energies; and beam energies
for the copper foil on top of stacked targets in Configurations E and F that were calculated using
this equation. Based on these results, the average beam energy at the midpoint of the top Cu foil
was 13.10±0.04 MeV. This translated to an entry beam energy of 13.285±0.065 MeV, which was
used for all calculations and simulations for all bombardments. Horizontal and vertical error bars
for the experimental points are plotted but small. (IAEA data from: IAEA/NDS.) (Image: Wooten,
et al., 2015. Image courtesy of Elsevier. Used with permission.)

2.2.4.5. Calculating Flux of Proton Beam
Similar to published methods (Lapi, et al., 2007; Kopecký, 1985; Greene and Lebowitz,
1972), the beam current was determined by production of

63

Zn in the Cu monitor foils. The

standard activation equation was used to calculate current:

!!"# = !"# 1 − ! !!!! ,

(2.5)

where AEOB is the activity of a product at EOB; n is the number of target nuclei per area; and ϕ is
the flux of beam particles passing through the target. The activity of
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63

Zn produced from the

nat

Cu(p,x)63Zn reaction was calculated as described in Section 2.2.4.3. The number of target

nuclei per area was calculated by the following equation:

n=!!

!
!!

ℎ ,

(2.6)

where NA was Avogadro’s constant; ρ was the density of Cu metal; Ar was the relative atomic
mass of the non-enriched Cu metal; and h was the individual thickness of the Cu foil (determined
by mass). To determine the cross-section for calculating beam current, we interpolated between
adjacent cross-section points (interval: 0.1 MeV) from the IAEA-recommended excitation curve
for the

nat

Cu(p,x)63Zn reaction (IAEA/NDS). Uncertainty in the beam energy was propagated

(Section 2.2.4.8) through the interpolation. Equation 2.5 was solved for ϕ, calculated based on
the production of 63Zn in the topmost Cu foil in each stacked foil target. The uncertainties in the
values entered in these calculations were propagated to give the uncertainty in the beam current
for that bombardment and eventually were propagated to the uncertainty of the proton energies in
the final results.

2.2.4.6. Calculating Nuclear Cross-Section Results
Cross-sections were measured solving Equation 5 for σ. The following values were used:
AEOB calculated for

52,52m,54

Mn in each Cr foil (Section 2.2.4.3); n calculated using the mean

thickness of our Cr foils; ϕ calculated for each bombardment; and tb=120±15 sec. We bombarded
three targets for each configuration, and the same beam energy was assumed for every foil in the
same position within a configuration, as calculated using the TRIM module. Cross-section results
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from foils across different configurations were grouped into “bins” based on beam energy. For
each bin, the energy and cross-section result (and uncertainties) were determined by inversevariance weighted averages in the x- and y-directions and reported as our final results (Figure
2.4-Figure 2.6, Table 2.2-Table 2.4). As not all irradiated chromium foils were counted soon
enough to detect 52mMn, our calculation neglects its contribution to production of 52Mn.

2.2.4.7. Calculation of Predicted Yields at Saturation
Cross-section results were used to calculate the saturation activity yield. The activation
equation (Equation 2.5) was used to calculate yields at saturation from our cross-section data,
with a proton flux of 1 µA. Table 2.5 shows the predicted saturation yields that we calculated for
each isotope product using our measured cross-section data.

2.2.4.8. Uncertainty Analysis
Error was propagated from the origin to final results as absolute uncertainty, not as
percentages. Uncertainties <0.05% were neglected. Instrumental uncertainty was considered for
every measurement, and random uncertainty was calculated for every repeated measurement and
for counting of a random process (i.e., gamma spectroscopy). Our statistics are presented in a
descriptive (not inferential) manner and thus we present the mean, standard deviation, and
sample size for all of our final cross-section results (Table 2.2-Table 2.4).
Instrumental uncertainty was typically either provided by the instrument, or otherwise
estimated to be ±0.5 times the most precise digit of the measurement from that instrument. All
random uncertainties were calculated as ± one standard deviation for a sample, population, or
Poisson distribution, and this standard deviation was propagated onward. For the foil counting,
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we estimated that the uncertainty in the net peak area to be one standard deviation of the Poisson
distribution (i.e., the square root of the number of counts in each peak). Whenever an average
was calculated, the error was expressed as either a sample standard deviation (for sample size, N,
<20) or a population standard deviation was calculated (e.g., for Monte Carlo results for ~1,000
transmitted ions from simulations in TRIM). Whenever a weighted average was appropriate, the
inverse-variance weighted mean, !! , was calculated by the equation:

!! !

!! =

!!

!!!

!!!

,

(2.7)

where xi is a measurement and si is the uncertainty in that value. This type of weighting
minimizes the uncertainty in the mean, which was:

!! !! =

!
!!

!!!

.

(2.8)

Uncertainties were propagated by applying the following equation (Arras, 1998;
Croarkin, 2003) for the propagation of relatively small uncertainties through any calculation that
used input values that had uncertainty:

!! ! =

!" !

! !!
!

!!! +

!"
!!! !!
!

!"
!!!

!!" ,

(2.9)

where s(f) is the error in the calculated value f; Xi is each variable used to calculate f; si is the
standard deviation in Xi; and sij is the covariance for variables i and j (for i ≠ j). Our only
51

correlated sources of error were the fitted parameters for our efficiency calibrations, so the
second term of Equation 2.9. This equation was zero for all other propagations of error. The
partial derivative(s) in Equation 2.9 account for the relative influences of the uncertainty of each
quantity on the uncertainty of the calculated quantity. All uncorrelated uncertainties for the same
value, such as rounding error, instrumental error, and statistical error, were added in quadrature
to give the total uncertainty for that quantity.

2.2.5. Chemical Separation
2.2.5.1. Chemical Isolation by Cation-Exchange Chromatography
Following a method published by Buchholz, et al. (2013), we used cation-exchange
chromatography to separate
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Mn from the chromium metal target after proton bombardment.

The irradiated chromium metal was dissolved in approximately 0.5-1 mL hydrochloric acid that
was diluted to a final concentrations of approximately 0.6-6.1 M. The solution was then
repeatedly evaporated and resuspended in sulfuric acid to replace the chloride anions with
sulfate, then diluted to form ~0.1 M sulfuric acid. Under these conditions, the solution was
transferred to a pre-conditioned column of AG 50W-X8 cation-exchange resin (Bio-Rad,
Hercules, California, United States). Much of the chromium(III) passed through the column and
was further eluted in 0.1 M sulfuric acid, while

52

Mn(II) was immobilized on the column.

Frequently, a visible band of Cr(III) was also immobilized on the column. Manganese-52(II),
along with this band of Cr(III), was eluted in ammonium citrate (which was used by Buchholz, et
al.), as well as aqueous solutions of ammonium oxalate, hydrochloric acid, or sodium(I) chloride.

52

Chloride (Cl-) anions were removed from the solutions of HCl and NaCl by evaporating
the product solution to dryness using heat and, sometimes, simultaneous evaporation with
nitrogen (N2) gas. To remove the oxalate and citrate anions from their respective solutions, the
solution was dried and elevated heat was used decompose those molecules, leaving behind a dry
residue containing metal solutes. This method had been validated previously by heating a visible
mass of ammonium oxalate until all visible solid had disappeared. The remaining dried

52

Mn

could be resuspended in another solvent, for example saline. Before animal injections, the pH of
the solution containing

52

Mn was tested and, if necessary, raised to the range of pH~4-7 using

dilute sodium hydroxide (NaOH).

2.2.5.2. Chemical Isolation by Anion-Exchange Chromatography
An alternative method for isolating

52

Mn from chromium metal was published recently

by Graves, et al. (2015), which utilized anion-exchange chromatography. The key to this method
was adding a large volume of ethanol to the digested target solution, presumably to complex with
the Cr(III) cations (Severin, 2015), which would leave more chloride ions to complex with the
Mn(II) cations. A method similar to the one described in the article was shared with us by the
authors before publication, and we rapidly adapted it as our preferred separation method.
First, the bombarded target was digested in ≤0.5 mL of concentrated (12.1 M)
hydrochloric acid with gentle heat. Next, 200 proof ethanol was added to make the resulting
solution 96% ethanol and 4% concentrated HCl (both percentages by volume). The resulting
solution was transferred to a pre-conditioned column of ~100-300 mg of AG 1-X8 strong anionexchange resin. Under these conditions, most Cr(III) ions were eluted, while Mn(II) was
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immobilized on the small resin column. After rinsing the column with additional 96%/4%
ethanol/HCl, most of the 52Mn(II) and Cr(III) that were on the column were eluted in dilute HCl.
Although the Cr(III) had decreased significantly from the original target solution, its
presence in the eluted product meant that the above separation procedure neeeded to be repeated.
Graves, et al. recommended performing the separation a total of three times. The eluted product
was dried down with heat and sometimes N2 gas and then redissolved in a small volume (~0.10.5 mL) of concentrated HCl. Next, 200 proof ethanol was added to make the resulting solution
into 96%/4% ethanol/HCl. In later experiments we were able to “recondition” the same column
by rinsing it with >10x column volume of each of the following solvents: 2 M HCl, 6 M HCl,
96%/4% ethanol/HCl, and water, always ending with the 96%/4% ethanol/HCl solution. The
52

Mn in ethanol/HCl was transferred to either a fresh, pre-conditioned column or the

“reconditioned” original column, and the separation process was repeated at least two more times
to further reduce Cr(III) content.
Chromium(III) content was determined at various check-points in the procedure using
microwave plasma atomic emission spectroscopy (MP-AES). These samples were tested for
Cr(III) by ICP-AES that had been calibrated using an atomic absorption spectroscopy (AAS)
standard solution for Cr(III) in dilute HCl. Additional metal contaminants were assayed by ICPAES following a similar procedure and using standard solutions for the corresponding metal
cation, always in dilute HCl.

2.2.6. Characterization of Products
The recovery of the separation was assayed by measuring the radioactivity of the product
using an ionization dose calibrator. The radionuclidic purity was tested using gamma-ray
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spectroscopy by calculating the amount of any radionuclide other than 52Mn and then expressing
this amount as a percentage of the total radioactivity or total number of radioactive atoms
detected by gamma-ray spectroscopy. Manganese-52m was removed by overnight decay, and
54

Mn was produced at a very low reaction rate because the

section that was ~10x lower than the

nat

nat

Cr(p,x)54Mn reaction had a cross-

Cr(p,x)52Mn reaction, presumably due to the low natural

abundance of 54Cr (n.a.=2.4%) needed for the 54Cr(p,n)54Mn reaction.
Since many transition metals form bold colors in solution, visual observation with the
unaided eye can be a good quick test for significant concentrations of the dissolved metal target
in the separated product. Since Cr(III) is green in solution, we could quickly oberve by eye the
presence of Cr(III) above a certain threshold. Future work would include developing a protocol
for determining effective specific activity (Section 5.2.5) by titration with a chelator, followed by
radio-TLC. DOTA has been show to be a suitable chelator for manganese (Graves, et al., 2015).
For all of the methods mentioned above for characterizing chemical purity, it is worth noting that
although 52,52m,54Mn all decay to stable daughter isotopes of chromium, and any other radiometal
contaminants would decay to stable daughter isotopes of other transition metals, none of these
stable daughters would be present in great enough concentrations to contribute significantly to
chemical impurities.
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2.3. Results
2.3.1. Nuclear Cross-Section Results
The stacked-foil experiments performed in this work produced cross-section data for the
nat

Cr(p,x)52,52m,54Mn reactions for proton energies <14 MeV. We did not observe any other

isotopes in the Cr foils from any other reactions or from the two other stable isotopes of Cr: 50Cr
(4.3% natural abundance) or

53

Cr (9.5% natural abundance). Our final cross-section results are

plotted in Figure 2.4-Figure 2.6.

2.3.1.1. natCr(p,x)52Mn
At low proton energies,
(threshold: 5.600 MeV;

52

(threshold: 13.688 MeV;

53

52

Mn was likely only produced by the

Cr: 83.8% natural abundance) as the

53

52

Cr(p,n)52Mn reaction

Cr(p,2n)52Mn reaction

Cr: 9.5% natural abundance) (BNL/NNDC/QCalc, 2014) has an

energy threshold above the upper limit for our calculated entry beam energy. Therefore, results
can be compared to published cross-sections for not only the natCr(p,x)52Mn reaction, but also the
52

Cr(p,n)52Mn reaction, after scaling down the published results from enriched targets based on

natural abundance of 52Cr. Results for the

nat

Cr(p,x)52Mn reaction are shown in Figure 2.4. Our

results are in agreement with published results for natural chromium targets (Buchholz, et al.,
2013; West Jr, et al., 1987; Barrandon, et al., 1975), as well as re-scaled results from enriched
targets (Levkovskij, 1991; Skakun, et al., 1986; Wing and Huizenga, 1962; Linder and James,
1959; Boehm, et al., 1952).
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Figure 2.4: Cumulative cross-section results for the natCr(p,x)52Mn reaction.
Other published data sets are also plotted, including rescaled results from enriched
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.)

Table 2.2 Cross-section results for the natCr(p,x)52Mn reaction.
Energy

Cross-Section

Ep
(MeV)

(b)

12.68±0.04
12.37±0.04
12.0±0.1
11.2±0.1
10.3±0.1
9.3±0.1
8.9±0.1
8.3±0.1
8.0±0.1
6.6±0.2

0.102±0.009
0.099±0.007
0.104±0.011
0.086±0.011
0.085±0.011
0.060±0.011
0.059±0.007
0.047±0.005
0.050±0.005
0.032±0.004

(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.)
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52

Cr targets.

2.3.1.2. natCr(p,x)52mMn
52m
52m

Mn has cross-sections roughly three times larger than

Mn can be produced by the

52

52

Mn in our energy range, and

Cr(p,n)52mMn reaction (same threshold as the ground-state

reaction) (BNL/NNDC/QCalc, 2014). Just as with the

nat

Cr(p,x)52Mn results, there are no

competing reactions that produce 52mMn from natural Cr in our proton energy regime. Therefore,
our cross-section results can be compared to published results for both the

nat

Cr(p,n)52mMn

reaction, as well as for the 52Cr(p,n)52mMn reaction, after scaling down the published results from
enriched targets based on natural abundance of 52Cr. Our results for the natCr(p,x)52mMn reaction
are shown in Figure 2. For this reaction product, only five values were reported because many Cr
foils were not counted quickly enough to detect

52m

Mn before it decayed. The results from

Barrandon, et al. (1975) are noticeably less than all other published results at Ep>10 MeV.
However, our results agree well with

52m

Mn cross-section data from other natural chromium

target publications that were also cited for 52Mn in Section 2.3.1 (Buchholz, et al., 2013; West Jr,
et al., 1987; Barrandon, et al., 1975), as well as re-scaled results from enriched targets
(Levkovskij, 1991; Skakun, et al., 1986; Wing and Huizenga, 1962; Linder and James, 1959;
Boehm, et al., 1952). It appears that the excitation peak from Barrandon, et al. (1975) is not as
high as all of these other published cross-sections, and our results are closer to the other studies.
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Figure 2.5. Cross-section results for the natCr(p,x)52mMn reaction.
Other published data sets are also plotted, including rescaled results from enriched
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.)

Table 2.3. Cross-section results for the natCr(p,x)52mMn reaction.
Energy
Ep
MeV

12.45±0.04
11.3±0.1
9.3±0.1
8.4±0.1
6.6±0.2

Cross-Section
b

0.274±0.022
0.233±0.042
0.246±0.043
0.209±0.028
0.116±0.023

(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.)
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52

Cr targets.

2.3.1.3. natCr(p,x)54Mn
54

Mn was detected in lower yields than

52,52m

Mn. The only logical reaction channel that

would have produced this isotope in natural Cr was the 54Cr(p,n)54Mn reaction (threshold: 2.200
MeV; 54Cr: 2.4% natural abundance) (BNL/NNDC/QCalc, 2014). Results were also compared to
cross-section results from enriched targets that were scaled down based on the natural abundance
of 54Cr. Our results for the

nat

Cr(p,x)54Mn reaction are shown in Figure 2.6. Only one published

data set was reported for the production of 54Mn from natural chromium with Ep≤30 MeV, and
this data set only included cross-sections for Ep ~17-38 MeV. Therefore, we compared our
results with published cross-sections from enriched

54

Mn targets (Levkovskij, 1991; Gusev, et

al., 1990; Skakun, et al., 1986; Zyskind, et al., 1978; Kailas, et al., 1975; Johnson, et al., 1960)
by rescaling the published cross-sections according to the natural abundance of 54Cr.

Figure 2.6. Cross-section results for the natCr(p,x)54Mn reaction.
Other published data sets are also plotted, including rescaled results from enriched
(Image: Wooten, et al., 2015. Image courtesy of Elsevier. Used with permission.)
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54

Cr targets.

Table 2.4. Cross-section results for the natCr(p,x)54Mn reaction.
Energy
Ep
MeV

Cross-Section

12.5±0.1
12.24±0.05
10.0±0.1
8.5±0.1
7.8±0.1

0.0105±0.0014
0.0138±0.0015
0.0146±0.0015
0.014±0.002
0.0147±0.0011

b

(Data: Wooten, et al., 2015. Data courtesy of Elsevier. Used with permission.)

2.3.1.4. Predicted Saturation Yields
Table 2.5 shows the predicted saturation yields for 52,52m,54Mn from natCr(p,x) reactions in
the range of proton energies that was encompassed in our cross-section results for each isotope
(Sections 2.3.1.1-2.3.1.3).

Table 2.5. Predicted yields for natCr(p,x) reactions at saturation.
Product

52

Mn
Mn
54
Mn

52m

Energy Range
Ep
MeV

Predicted Yield at Saturationa
Ypredicted
mCi· A-1
GBq· A-1

12.7à6.6
12.4à6.6
12.5à7.8

27.1±1.0
82.2±5.1
4.5±0.2

1.00±0.04
3.0±0.2
0.165±0.008

a

Saturation defined as bombardment time, tb=10t1/2. (Data: Wooten, et al., 2015. Data courtesy of
Elsevier. Used with permission.)

2.3.2. Chemical Separation of 52Mn
For the cation-exchange method, Figure 2.7 shows elution profiles for Cr(III), eluted in
0.1 M H2SO4 and measured by UV-Vis spectroscopy, plotted along with 52Mn, eluted in various
solutions and measured by radioactivity using a gas ionization dose calibrator. Not shown in
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Figure 2.7 is the quantity of Cr(III) that was present in the eluted product, which was also visible
often, especially when the volume of the product was concentrated. Preliminary separations
using the anion-exchange isolation method demonstrated approximately equivalent durations for
the procedure and resulted in lower recovery rates that were in the range of 40-70% (without
decay correction).

Figure 2.7. Elution profiles showing the elution of Cr(III) in 0.1 M H2SO4 and 52Mn(II) in
various eluents.
Cr(III) was measured by ultraviolet-visible spectroscopy, and 52Mn(II) was measured by
radioactivity using a gas ionization dose calibrator. Solid and hollow symbols with the same shape
correspond to the same experiment. The gap between plots includes intermediate rinses with
various solutions between eluting Cr(III) and 52Mn(II). Not plotted: Cr(III) eluted after the initial
elution of Cr(III), such as with the 52Mn product or in any of the intermediate rinses.

2.4. Discussion
We have bombarded 2-3 stacked Cr foils with thickness of ~60-90 µm with ~13-14 MeV
protons at 10-15 µA beam current. Typically, the top Cr foil contains enough activity for each
subsequent experiment, but this incident beam energy only exploits approximately half of the
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excitation peak for the

52

Cr(p,n)52Mn reaction. At proton energies of 13-14 MeV greater

activities are required for scaled-up production, an incident proton energy of ~24 MeV and a
thicker Cr metal target could significantly increase bombardment yields for

52

Mn, while

radiocontaminants could still be removed: 51Cr (t1/2=27.7 days) by chemical separation with the
Cr target material, and 51Mn (t1/2=46.2 min.) by radioactive decay.
Reliable cross-section data that includes results from multiple groups is beneficial for
confirming cross-section results, which in turn affect several parameters for accelerator-based
isotope production that are essential to product yield and radionuclidic purity. However, few
published studies currently exist for the reaction channels that produce 52gMn and other isotopes
from bombardment of natural Cr with protons at energies <14 MeV, which is an important
energy range for many biomedical cyclotrons worldwide. In this work, we have measured crosssections for the

nat

Cr(p,x)52,52m,54Mn reactions. Our results were in general agreement with

published results from natural Cr targets and re-scaled results from isotopically enriched Cr
targets. Cross-section results reported here will contribute to more accurate yield predictions and
enhanced radionuclidic purity in the production of the isotopes studied here, particularly 52Mn.

2.5. Conclusions and Recommendations
•

Nuclear cross-sections have been measured for the

nat

Cr(p,x)52,52m,54Mn

reactions for incident protons with energy ≤13 MeV, which is easily achieved
by most cyclotrons at medical centers. The cross-section results agreed closely
with theoretical simulations, and they can be used to predict yields of
52,52m,54

Mn when bombarding natural chromium with low-energy protons.
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•

Chemical isolation was performed using a published method that involved
digesting the chromium target in HCl, replacing the HCl with dilute H2SO4
and then immobilizing

52

Mn(II) on a cation-exchange column. This method

resulted with visible amounts of Cr(III) in the product.
•

Chemical isolation using a recently published method was more effective.
This method involved digesting the chromium target in HCl, diluting this
solution in ethanol, immobilizing 52Mn(II) on an anion-exchange column, and
performing this process repeatedly.

•

Recommended future directions: Trace metal analysis after each round of the
anion-exchange separation method to determine how many rounds are
necessary; characterization of routine production including cyclotron yields,
chemical recovery percentage, radionuclidic purity, and trace metals analysis.
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Chapter 3. Biodistribution and PET Imaging
of 52Mn1,2,3,4
3.1. Background
Although imaging of accumulated Mn(II) is possible by T1-weighted MRI, truly
quantitative measurement of the biodistribution of manganese in vivo is difficult. Direct,
quantitative testing of manganese concentrations in humans is difficult because the exact
ingested or inhaled dose is typically unknown. However, preclinical imaging and biodistribution
studies using tracer amounts of radiomanganese provide a route to quantify the amount of
manganese as a percentage of administered dose in animal models. Past studies have examined
the biodistribution of manganese in various forms administered by different routes in rodents and
fish, and have generally found that manganese is distributed to many tissues throughout the
body. Several studies have shown the distribution of manganese using the radiotracers
54

1

52

Mn or

Mn, or utilizing stable manganese (55Mn: 100% natural abundance) (Baum, et al., 2010) and a
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non-radioactive technique for quantifying metals. In this work, we utilized the isotope

52

Mn to

study the biodistribution of injected and inhaled solutions of free manganese in mice and rats.
As discussed in Section 1.4,

52

Mn is a radiotracer with a half-life that is useful for

biomedical studies and emits positrons with a high enough branching ratio to make it a realistic
radionuclide for in vivo imaging by PET. Therefore, we also performed a PET imaging study in
mice following I.V. administration of

52

Mn in aqueous solution. CT imaging of the same mice

provided anatomical imaging, and ex vivo biodistribution after completion of all imaging
confirmed quantification of the distribution of 52Mn that was visualized in the PET images.
In the literature, free manganese has been shown to accumulate in the human pancreas
following administration of a weakly bound manganese(II) chelate for manganese-enhanced
MRI (MEMRI) (Botsikas, et al., 2012). Published ex vivo biodistribution results (Graves, et al.,
2015) and our own results determined that the pancreas tends to accumulate and retain free
manganese. Studying uptake of

52

Mn(II) by the pancreas is of interest for possible imaging

applications related to diabetes, which showed significantly lower uptake of the MEMRI contrast
agent in humans (Botsikas, et al., 2012). Since many diabetes studies use rats as animal models,
and since rats have larger organs that can be better for imaging than in mice, we also studied the
biodistribution of manganese in rats. Relatively long timepoints up to seven days post-injection
were examined to allow time for manganese to decrease in tissues near the pancreas to increase
contrast on PET imaging. After performing a biodistribution study in rats at these timepoints,
PET/CT imaging studies were also performed.
This chapter presents experiments using animal models investigating the biodistribution
for free

52

Mn that was administered in either saline or water. The biodistribution results and

PET/CT images presented here are potentially useful as supporting information for

69

environmental and occupational regulations, for designing PET studies utilizing free 52Mn, such
as pancreas imaging in diabetes applications, and for predicting biodistribution of free
manganese that might dissociate in vivo from a MEMRI contrast agent.

3.2. Experimental
3.2.1. Radionuclide Production
The radioactivity that was used in this chapter was produced and isolated using methods
that are described in Section 2.2.5. In almost every production, the 52Mn was eluted in HCl, the
product was dried down, then resuspended in saline. If necessary, the pH of the resuspended
saline product was adjusted with HCl and/or NaOH.
However, for the PET/CT imaging (and post-imaging ex vivo biodistribution) in mice, the
52

Mn was eluted in 0.067 M ammonium oxalate solution, and the ligand was removed in the

following manner. The ammonium oxalate product was heated to dryness, and then the heat was
increased to burn away the ammonium oxalate, leaving behind a residue containing 52Mn in the
vessel. The remaining

52

Mn was resuspended by adding water followed by a drop of 6 M

hydrochloric acid, then heated to dryness. This evaporation and resuspension was repeated
without any hydrochloric acid, then the

52

Mn was finally resuspended in water, resulting in a

solution with pH of ~6.5, so pH adjustment was not performed because this pH was considered
safe for intravenous injection in the mice.
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3.2.2. Animal Models
All animal models used in this dissertation were purchased from Charles River
Laboratories (Wilmington, Massachusetts, United States). Mice were allowed to eat and drink ad
libitum, except for during handling, injection, and imaging until sacrifice. No mice in any group
died during injection, inhalation or otherwise prior to their designated timepoint. All animal
keeping and husbandry conformed to regulations of the Division of Comparative Medicine
(DCM) at WUSM, and all experiments involving animal subjects were performed under a
protocol that was approved by the Animal Studies Committee of WUSTL.
The biodistribution-only studies in mice that compared intravenous injection and aerosol
inhalation were performed using male CD-1 mice. The PET/CT and post-imaging biodistribution
study was performed using two male C57-Black-6 mice. All rat studies used male SpragueDawley rats.

3.2.3. Intravenous Injection of 52Mn
Mice and rats were injected via tail vein with ~100 µL volume that contained: ~5-10 µCi
for biodistribution-only studies and ~80-120 µCi for PET imaging studies of rats. For the mouse
PET/CT, each animal was injected with 41 µCi of 52Mn in 50 µL volume. The sample sizes for
the studies included in this chapter were as follows: n=4 for biodistribution-only in mice, n=3 for
biodistribution only in rats, and n=2 for PET/CT imaging in mice or rats.
The standard dose for administration was based on a single extra syringe of the dose that
was weighed before and after expelling its contents to determine the mass of this liquid. The
expelled contents were diluted to 100 mL volume, and then the radioactivity was measured in an
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aliquot from this dilution. This result was used to calculate the concentration of activity of the
original dose solution.

3.2.4. Inhalation of Aerosols Containing 52Mn
The inhaled doses of

52

Mn salt solutions were administered to mice as previously

reported by our group (Aweda, et al., 2013; Aweda, et al., 2015) using other radiolabeled
compounds. Solutions were loaded into a Small Volumetric Mean Diameter (VMD) Nebulizer
Unit (Aeroneb Lab, Aerogen, Dangan, Galway, Ireland) with the following specifications
(Aerogen, 2004): >0.1 mL·min-1 flow rate, 4.0-6.0 µm VMD, <0.2 mL residual volume. The exit
port of the nebulizer was inserted into a chamber made from a clear plastic (Figure 3.1).
Four mice were inserted individually into four tubes with a plastic plunger to gently push
their body to the front of the tube and their snout through a small opening at the opposite end of
the tube. The

52

Mn solution was pipetted into the liquid reservoir of the nebulizer and then the

nebulizer was powered on, producing an aerosol that filled the chamber. The mice were allowed
to inhale the aerosol for ~4-7 min., then the tubes were detached, and the mice were removed
from their tubes. One of the mice from each inhalation group of four mice was euthanized
immediately to serve as the standard dose received for its cohort—before activity could be
excreted from its body. The remaining three mice would be used for ex vivo biodistribution
studies, so the biodistribution results for each timepoint after inhalation of
mice.
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Mn represent n=3
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At each timepoint post-administration, the mice or rats for that timepoint were
euthanized, dissected, and each tissue was weighed and analyzed for radioactivity (Beckman
Instruments, Irvine, California, United States) (De Silva, et al., 2012). The radioactivity in the
diluted standard dose solution for the intravenous cohort (Section 3.2.3) and the carcass of the
standard dose mouse from the inhalation cohort (Section 3.2.4) were each measured in the same
manner. The percentage of injected or inhaled dose per gram of tissue (%ID/gram) was
calculated. When comparing the results from these studies, we examined the magnitude of the
uptake of 52Mn in tissues as %ID/gram and as a function of time and mode of administration.

3.2.6. PET/CT Imaging
To reduce scanner time and because these mice were small enough, all imaging in the
mouse study was performed simultaneously for both mice lying together side-by-side on a

73

specially made bed of each scanner. Rat imaging was performed individually. Shortly before
each timepoint for PET imaging, anatomic images were obtained by non-contrast CT using an
Inveon small animal PET/CT scanner (Siemens Preclinical Solutions, Knoxville, Tennessee,
United States). CT imaging was repeated before each timepoint for PET imaging.
PET imaging was performed using either the Inveon PET/CT scanner or a microPET
Focus 220 scanner (Siemens Preclinical Solutions). Static PET data were acquired for 30 minutes
at the 1-hour timepoint and for 1 hour at the 3-day timepoint. Attenuation maps for each subject
were obtained from either the CT scan in the Inveon scanner or by a transmission scan on the
Focus 220 scanner. Images were analyzed using Inveon Research Workplace software (Siemens
Preclinical Solutions).

3.3. Results
Figure 3.2 shows the results from ex vivo biodistribution of 52Mn in saline administered
via intravenous injection or by inhalation. Manganese-52 was cleared rapidly from the blood, as
demonstrated by its rapid decrease from 1 to 24 hours p.i., and the activity in the gastrointestinal
tract—stomach and intestines—also decreased rapidly between those same timepoints. At 1 hour
p.i., the highest activity was found, in decreasing order, in the liver, kidney, lung, heart,
pancreas, spleen, and salivary glands; however, by 24 hours p.i., the concentration of 52Mn in all
of these organs of high initial uptake had decreased greatly, except for the salivary glands,
pancreas, and kidney. Among the tissues that had lower initial uptake at 1 hour p.i.,
retained, to various degrees, in the brain, bone, and thyroid.
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Mn was

Figure 3.2. Plot showing results from ex vivo biodistribution of saline solutions containing
52
Mn administered via intravenous injection or inhalation.
The timepoints shown represent time after administration of the dose. Sample sizes for each
timepoint were n=4 mice for injection and n=3 for inhalation. Error bars: negative error bars not
shown for visual clarity; error bars represent statistical uncertainty across animals in each cohort
and no propagated uncertainty from other sources of uncertainty.

The results from inhalation show high concentration of 52Mn at 1 hour p.i., in decreasing
order, stomach, intestines, lung, and thyroid. From the data at 24 hour p.i., 52Mn was detected in
the lungs and thyroid, but it was cleared from the stomach and intestines. Additionally, low
activity of 52Mn was observed in the blood, suggesting that manganese was cleared rapidly from
the blood, just as in the results from IV injection. Figure 3.2 also shows that, from 1 to 24 hours
p.i., 52Mn accumulated in the kidney, pancreas, brain, liver, and spleen.
Figure 3.3 shows co-registered PET/CT images of the exact same two mice at 1 hour and
3 days following intravenous injection of 52Mn in aqueous solution. The PET signal in this figure
had been windowed for ease of visualizing signal from the abdomen. At 1 hour post-injection,
52

Mn is observed in the digestive tract, kidneys, and likely the pancreas, although the pancreas is
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difficult to identify definitively. At 3 days post-injection, the 52Mn left the digestive tract, while
it is retained in the kidneys, as well as liver, pancreas, and thyroid gland. Figure 3.4 shows the
results from the ex vivo biodistribution measurements that were performed after all PET and CT
imaging were completed at 3 days post-injection.

Figure 3.3. PET/CT images of mice at 1 h and 3 days following intravenous administration of
52
Mn in aqueous solution, windowed for visualizing activity in the abdomen.

Figure 3.4. Results from ex vivo biodistribution performed shortly after imaging at 3 day
timepoint.
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The biodistribution results from CD-1 rats at 1 hour, 1 day, 3 days, and 7 days post
injection of 52Mn are shown in Figure 3.5.

Figure 3.5. Biodistribution results of 52Mn isolated by anion-exchange chromatography and
administered in a saline solution by intravenous injection into male CD-1 rats.
The timepoints shown represent time from administration until sacrifice of rats. For each
timepoint of intravenous injection, n=3.

Figure 3.6. Excretion profile for male rats from the 7-day cohort that received intravenous
administration of [52Mn]MnCl2.
Excretions were collected at 1 hour, 1, 3, and 7 days, so the timepoints plotted above are at the
midpoint of each collection period. Error bars represent statistical uncertainty across animals in
each cohort and no propagated uncertainty from other sources of uncertainty.
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Figure 3.7 shows a typical co-registered PET/CT MIP image of a CD-1 rat at 7 days postinjection of 52Mn, windowed for visualizing radioactivity in the abdomen, and Figure 3.8 shows
the excretion profile and post-imaging biodistribution for the CD-1 rats (n=2) that were imaged
by PET/CT.

Figure 3.7. Approximately ventral view of a maximum intensity projection (MIP) image of
PET signal co-registered with CT image of a male CD-1 rat at 7 days following intravenous
administration of 52Mn in saline.
CT was windowed for visualization of skeleton; PET signal was windowed for improved
visualization of PET signal from the abdomen.
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Figure 3.8. Post-imaging biodistribution results of 52Mn in male CD-1 rats.
Animals euthanized 7 days post-injection of 52Mn (n=2).

3.4. Discussion
For the comparison of IV injection to inhalation of
52

52

Mn in mice, the concentration of

Mn in most tissues at both 1- and 24-hour timepoints is higher than in the inhalation results.

The activity in the gastrointestinal tract was much greater in the inhalation results, suggesting
that some of the dose may have been either swallowed directly from the aerosol or inhaled,
cleared by mucociliary clearance, and then swallowed. Also in our studies, we observed uptake
in the pancreas and brain, while 52Mn that entered the stomach or intestines did not appear to be
retained, although the one hour amounts were much higher in the inhalation groups likely due to
putative swallowing of some of the dose. Retention of

52

Mn in the brain, thyroid, and thymus

was observed in results from both injection and inhalation. We also found significant uptake of
52

Mn at 24 h in the bone (2.6%) resulting from injection, but not from inhalation.
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For both injection and inhalation,

52

Mn was cleared rapidly from the blood, and the

injection data showed 52Mn in the liver and kidney in <1 hour. The inhalation data also suggest
accumulation in the liver and kidneys, but this accumulation took much longer than one hour.
Although manganese appears to accumulate in both liver and kidneys, results from the literature
(Cikrt, 1972; Bertinchamps, et al., 1966; Papavasiliou, et al., 1966; Kato, 1963) suggest that very
little manganese is excreted in urine. Instead, the vast majority of manganese is excreted in feces,
primarily due to release of manganese from the liver into the enterohepatic circulation. In other
studies, animals that were administered manganese or radiomanganese intravenously (Ni, et al.,
1997; Chauncey, et al., 1977; Hughes, et al., 1966; Kato, 1963; Koshida, et al., 1963; Fore and
Morton, 1952b), high uptake was generally observed in the kidney, pancreas, liver, adrenal
glands, and intestine, as well as comparatively small amounts in the brain. Brain, et al. (2006)
and Helig, et al. (2006) reported that, for intratracheal instillation,
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MnCl2 was retained in the

lungs to a large extent but was also found in significant concentrations in the intestines, liver,
kidneys, and in a small concentration in the brain. These intratracheal instillation studies also
showed that Mn can enter the bloodstream from the lungs, possibly by ion channels, but not by
the divalent metal transporter-1 (DMT-1) in that particular tissue (Brain, et al., 2006; Heilig, et
al., 2006). These general trends in manganese distribution agree with studies that focused more
narrowly on the in vitro or in vivo uptake of manganese by cells or tissues that included liver
(Kodama, et al., 1991; Cikrt, 1972), kidney (Kodama, et al., 1991), pancreas (Kodama, et al.,
1991), intestines (Brain, et al., 2006; Leblondel and Allain, 1999), salivary glands (Seshadri and
Hoy, 2010; Ni, et al., 1997), myocardium (Chauncey, et al., 1977), and bone (Fore and Morton,
1952a).
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Owing to its neurotoxic effects, particular interest has been paid to uptake of manganese
in the brain by various routes. Kanayama, et al. (2005) administered to mice by eight different
routes a solution containing sixteen different radiotracers, mostly transition metals, and, for most
administration routes, 54Mn(II) had higher brain uptake than most of the other tracers. In several
other studies, rodents received radiomanganese by carotid injection or continuous in situ brain
perfusion brain. These studies suggest that manganese enters the brain by more than one
mechanism, including carrier-mediated uptake of Mn-citrate (Crossgrove, et al., 2003), by storeoperated calcium channels as Mn(II) (Crossgrove and Yokel, 2005), by transferrin-receptor
mediated endocytosis as Mn-transferrin (Aschner and Gannon, 1994; Aschner and Aschner,
1990), or by other unspecified mechanism(s) that are faster than simple diffusion (Aschner and
Gannon, 1994; Rabin, et al., 1993). In a comparison of

54

Mn species administered by in situ

brain perfusion, Mn-citrate was transported across the blood-brain barrier faster than either free
Mn(II) or Mn-transferrin, suggesting that Mn-citrate might be an important route for manganese
uptake in the brain (Crossgrove, et al., 2003). Furthermore, it appears likely that manganese
could accumulate in the brain because it appears to efflux at a rate that is consistent with simple
diffusion (Yokel, et al., 2003; Yokel, 2002).
Since it is known that certain inhaled substances can enter the brain directly from the
olfactory bulb—without entering the bloodstream—there have been a considerable number of
studies examining the possibility of manganese entering the brain by such mechanisms.
Characterization of this mechanism(s) would be particularly relevant to the problem of inhaled
manganese in metal workers. Animal studies using radiomanganese (Tjalve, et al., 1996; Tjalve,
et al., 1995) or MEMRI (Pautler, et al., 1998; Serrano, et al., 2008), suggested that Mn(II) can be
transported from the olfactory bulb and into olfactory neurons, transported through those
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neurons, across synaptic junctions, into secondary olfactory neurons, and then into the
diencephalon and cerebrum, and (in rats) into the spinal cord. Thompson et al. (2007) tested
uptake in rats with defective divalent metal transporter-1 (DMT-1) proteins and confirmed that
this transporter is involved in manganese uptake in the rat olfactory bulb based on higher uptake
in healthy control rats. In rats, ninety minute nose-only inhalation of aerosolized [54Mn]MnCl2
(Brenneman, et al., 2000) or [54Mn]MnHPO4 (Dorman, et al., 2002) solution leads to uptake in
the olfactory bulb and olfactory tubercle. In both studies, they observed uptake in lungs, liver,
kidney, and pancreas, and—at much lower amounts—in the striatum of the brain. In a similar
study, Lewis, et al. (2005) exposed mice and rats to nebulized, non-radioactive MnCl2 for 10
nose-only doses of 6 hours each. Sample analysis by proton induced X-ray emission (PIXE)
revealed elevated manganese in trigeminal ganglia, suggesting this nerve as a possible pathway
for brain entry of manganese.
In our studies, relatively high uptake was observed in the lung and thyroid following
either route of administration. Although several papers confirmed thyroid uptake of manganese
from different administration routes in animal models (Nishida and Kawada, 1992; Kawada, et
al., 1985; Deysach and Ray, 1949; Ray and Deysach, 1942), the biology of uptake of manganese
in the thyroid does not seem clear (Nishida and Kawada, 1992). Interestingly, electron spin
resonance (ESR) has shown that only a small fraction of the manganese naturally found in the rat
thyroid is in the 2+ oxidation state (Sakurai, et al., 1985), perhaps suggesting that it is bound to
serum protein(s) as Mn(III) and not present as a free Mn(II). Additionally, following
subcutaneous injection of Mn(II)Cl2, in guinea pigs (Deysach and Ray, 1949), manganese rapidly
accumulated in thyroid by 24 hours p.i., but then 70% of the manganese in the thyroid at 24
hours had cleared by 48 hours p.i.; and then 85%, by 96 hours p.i. Inhaled manganese uptake in
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salivary glands was in agreement with observations in welders exposed to manganese (Wang, et
al., 2008). Interestingly, our results showed that injection of 52MnCl2 exhibited higher and faster
uptake in salivary gland than in the inhalation study. Our results demonstrate uptake of 52Mn in
the brain, thyroid, and pancreas in all trials. Interestingly, uptake from IV administration was
higher in brain and pancreas, but lower in thyroid, compared to inhalation results. Also, IV
administration resulted in very high activity in salivary glands. Manganese-52 might someday be
used as a PET agent for niche clinical research applications, but our biodistribution results in
mice can be used, in conjunction with other published results, to inform regulations for safe
levels of environmental and occupational exposure to manganese.
Additionally, we have presented PET/CT images that visualize biodistribution of free
52

Mn(II) in mice, along with results from ex vivo biodistribution that was performed after

imaging. The distribution of PET signal in the images from the final timepoint generally agrees
with the biodistribution results. Building off the results presented, ongoing and future work could
include: using a more effective method for separating 52Mn from a chromium metal matrix; more
complete characterization of the separated

52

Mn product, including radionuclidic purity, trace

metals analysis, and/or effective specific activity titration; examining biodistribution at longer
timepoints than 24 hours; contrast-enhanced CT that will reveal the pancreas on CT, making it
possible to draw ROIs on the CT images for PET quantification; and possible applications in
PET imaging of diseases that can alter the absolute magnitude or relative distribution of
manganese in vivo.
One factor that motivated our interest in PET imaging of pancreas function with free
cations of radiomanganese was a MEMRI study by Botsikas, et al. (2012). In that study, humans
were imaged by T1-weighted MRI, and the signal in the pancreas of a normoglycemic (non-
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diabetic) person increased dramatically (became brighter, as shown in Figure 3.9) after
intravenous infusion of the manganese chelate mangafodipir trisodium (manganese dipyridoxal
diphosphate (Mn-DPDP), Teslascan, GE Healthcare, Amersham, Buckinghamshire, United
Kingdom; See Section 1.2.3). For patients with diabetes, signal also increased after infusion of
mangafodipir, but by a significantly (p=0.01) smaller increase. Patients with advanced diabetes
that required insulin treatment demonstrated even smaller average increase that was also
significantly (p=0.007) less than the control group. Mangafodipir is a weakly bound chelate, and
a significant portion of it dissociates in vivo (Gallez, et al., 1996; Harisinghani, et al., 2001), so it
was likely that at least some of the enhanced signal observed by Botsikas, et al. was from free
Mn(II) cations and not only from chelated Mn(II)-DPDP. This is not surprising because
pancreas, like several other organs, naturally takes up manganese (Yokel, 2009). Uptake of
manganese by healthy pancreas was further confirmed in our own ex vivo biodistribution studies
in mice and rats, as well as in another similar study using radiomanganese (Graves, et al., 2015).
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Figure 3.9. T1-weighted MRI images of a normoglycemic (non-diabetic) human and a human
with type 2 diabetes.
Left column: normoglycemic patient; right column: patient with type-2 diabetes mellitus; top row:
before contrast; bottom row: 20 min. following administration of Mn-DPDP, a manganese-based
T1-shortening contrast agent. The graph at far right shows statistically significant lower
enhancement of MR signal in patients with diabetes compared to normoglycemic controls. (Image:
Botsikas, et al., 2012. Image courtesy of Taylor & Francis. Creative Commons.)

Based on this knowledge, we endeavored to use

52

Mn for PET imaging of pancreas

function. For sufficient contrast to observe the pancreas, the signal from the pancreas needed to
be significantly greater than from nearby tissues. Therefore, the high 52Mn radioactivity that we
observed in the liver and kidneys at 24-hour post-injection might pose a problem for imaging
with 52Mn at those timepoints. Therefore, we examined the biodistribution of free 52Mn injected
intravenously into healthy normal rats at timepoints extending up to 7 days. The results (Figure
3.5) showed that indeed the 52Mn was retained at a higher level than the liver or kidneys at the
longer timepoints of 3 and 7 days. For the same injections, we also examined the excretion
profile of

52

Mn, and the results (Figure 3.6) agree with what we found in the literature that
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manganese is excreted almost exclusively by the liver-bile-feces system, rather than through the
kidneys and into the urine. The PET/CT imaging study in general-use rats (CD-1) revealed that
by waiting 7-days post-injection can indeed provide adequate signal and contrast to visualize a
healthy pancreas. A MIP of the co-registered PET/CT images (Figure 3.7) clearly shows signal
from liver and kidneys, but much stronger signal from the region of the pancreas. This signal
from the pancreas was confirmed by post-imaging ex vivo biodistribution (Figure 3.8).

3.5. Conclusions and Recommendations
•

Biodistribution studies of intravenously injected

52

Mn(II) in mice showed

uptake in many organs, most interestingly: salivary glands, brain, thyroid,
thymus, pancreas, liver, kidney, and bone.
•

Similar studies in rats that extended to longer timepoints showed that activity
in all of those organs decreases significantly over the course of seven days,
except for brain, adrenals, and pancreas and confirmed that manganese is
excreted almost exclusively through the feces and not the urine.

•

Biodistribution studies of inhaled manganese in mice showed uptake in lung,
brain, thyroid, pancreas, liver, and kidney.

•

PET imaging of [52Mn]MnCl2 in mice and rats confirmed the observations
from biodistribution, including high signal from 52Mn in the pancreas at seven
days post-injection, after the activity had significantly decreased in nearby
tissues, such as the liver and kidneys.
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•

Recommended future directions: PET/CT imaging using a CT contrast agent
that will reveal the pancreas on CT, which will enable quantitative imaging of
free manganese in the pancreas with possible applications in diagnostic
imaging of diabetes.
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Chapter 4. Applications for 52Mn in PET/MR
Imaging1,2,3
4.1. Background
An additional motivation for understanding the biodistribution of free manganese is that
manganese(II) has been utilized in contrast agents for MR imaging. Manganese(II) is considered
to be “high-spin” from its five unpaired valence electrons (Weinmann, et al., 1984; Wolf, et al.,
1985), which shorten the spin-lattice time constant (T1) for nearby 1H nuclei, resulting in brighter
signal when using a T1-weighted MR pulse sequence (Pan, et al., 2010; Rodriguez-Vargas, 2010;
Silva and Bock, 2008), especially in anatomical regions with high water density. Since MRI is
not inherently as quantitative as PET, and since MEMRI are not as widely studied as Gd-based
agents, it could be useful to “authentically” radiolabel manganese-based MR contrast agents with
radiomanganese (Klein, et al., 2005; Coenen, et al., 2014) for quantitative confirmation of their
biodistribution—by dissection, autoradiography, and/or in vivo imaging.
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4.2. Experimental
4.2.1. MRI Phantom Imaging and Measurement of Relaxivity
In magnetic resonance techniques, including MRI, the magnetic spins of a sample are
aligned to a strong external magnetic field and then a radiofrequency electromagnetic pulse
temporarily realigns the magnetic spins of a selected frequency—typically the frequency of 1H in
the case of MRI. The exponential relaxation of nuclear spin to the original magnetic field is
described by the spin-lattice relaxation constant (T1), which is typically expressed in seconds.
The T1 relaxivity (r1) of a T1 contrast agent is often expressed in mM-1·sec-1 (or similar units) and
is the primary quantity used to compare the capability of a contrast agent to shorten T1 for nearby
nuclei. This change in T1 causes brighter MR signal in that vicinity when imaging is performed
using a T1-weighted pulse sequence.
We measured T1 for several concentrations of Mn(II) in aqueous solution using an
inversion-recovery experiment. Aqueous solutions of several different concentrations of
Mn(II)Cl2·4H2O, ranging from 10 µM to 2 mM were prepared, and placed in several different
conical centrifuge tubes upright in a rack. This rack was imaged using a birdcage head coil in the
human-sized Biograph mMR PET/MR scanner (Siemens Medical Solutions USA, Malvern,
Pennsylvania, United States) at the Center for Clinical Imaging Research (CCIR) at WUSM. The
imaging was performed by an inversion-recovery MR pulse sequence at a range of values for the
inversion time (TI). In this experiment, the real component of MR signal—positive or negative—
in each concentration of MnCl2 was imaged. Using the ImageJ software (Ferreira and Rasband,
NIH/NIMH), the signal in the cross-section of each tube and the background was measured, and
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the signal intensity (SI) from the background was subtracted from all signals. This was repeated
for all values of TI, and the values for SI were plotted versus TI for each concentration of Mn(II).
Using the Curve Fitting Toolbox in the MATLAB software (MathWorks, Natick,
Massachusetts, United States), the signal intensity (SI) versus TI data were fit to the equation
(Hashemi, et al., 2010):

!" ∝ !! 1 − 2! !!"

!!

+ ! !!"

!!

,

(4.1)

where M0 is the original longitudinal magnetization in arbitrary units, and TR is repetition time of
the pulse sequence in sec. The result of the fit was a value for (T1), expressed in seconds, for
each concentration of Mn(II). The relaxation rate (R1), which is expressed in sec-1, for each
concentration, was simply the inverse of T1, and r1 was the slope of the linear fit of R1 versus
concentration of Mn(II).

4.2.2. PET/MR Phantom Imaging
This experiment was repeated as a PET/MR imaging study. Aqueous solutions of
Mn(II)Cl2·4H2O were prepared in concentrations ranging from 10 µM to 2 mM and added
different amounts of radioactivity of 52Mn(II) ranging from 2-12 µCi. PET data was collected for
30 min. and MR images using an inversion recovery sequence for a variety of values for TI, with
TE=12 msec using the Biograph mMR.
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4.3. Results
A typical MR image from a phantom that included several different concentrations of
non-radioactive Mn(II) at a few selected inversion times is shown in Figure 4.1. The signals
resulting from an inversion-recovery sequence with numerous inversion times is shown in Figure
4.2, and the corresponding results for R1 are plotted versus concentration of Mn(II) are plotted in
Figure 4.3. The slope of the linear fit through those data yields the relaxivity of Mn(II)—
specifically MnCl2·4(H2O)—in water as r1=8.6 mM-1sec-1.

Figure 4.1. Phantom design and images from inversion-recovery MRI experiment with
different concentrations of Mn(II) in water imaged at many different inversion times (TI).
Images from only four of the TI values are shown here.
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Figure 4.2. Results from inversion recovery experiment for several concentrations of Mn(II)
solutions in water.
Signal acquired by real-component acquisition, signal from a region of the background was
subtracted from all samples, and fitted to the equation shown. (Equation: Hashemi, et al., 2010).

Figure 4.3. Plot of longitudinal relaxation rate (R1) versus concentration of Mn(II) based on
inversion recovery experiment.

95

Figure 4.4 shows the imaging results from PET/MR imaging of a phantom of aqueous
solutions of different concentrations of non-radioactive Mn(II) as MnCl2·4(H2O) and radioactive
52

Mn(II). In both panels of Figure 4.4, the TE for MR and the PET imaging parameters were

constant; however, the left panel shows MR signal from a pulse sequence with short TI and short
TR, while the right panel shows MR signal from a pulse sequence with long TI and long TR.

Figure 4.4. PET/MR images of phantom consisting of conical tubes containing aqueous
solutions of different amounts of non-radioactive MnCl2·4(H2O) and radioactive 52Mn(II).
Images acquired in a Siemens mMR human scanner. PET: 30 min. acquisition; attenuation
correction based on a Dixon sequence. MR: magnitude acquisition in an inversion-recovery
sequence (left panel: TR=3 sec, TE=12 msec, TI=50 msec; right panel: TR=10 sec, TE=12 msec,
TI=9.93 sec).
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4.4. Discussion
The curve fits for both SI versus TI and R1 versus [Mn(II)] were both very close, and the
latter fit produced a result for r1 that was close to published values. These r1 values are less than
for Gd(III) because it has seven unpaired valence electrons versus five for Mn(II), and the
number of unpaired valence electrons is the most important characteristic of a T1-shortening
contrast agent for MRI. The results from MRI-only images and quantification informed our
selection of concentrations of non-radioactive Mn(II) for our phantom for PET/MR imaging. The
PET/MR images demonstrated the feasibility of PET/MR imaging of dual-modality contrast
agents that incorporate non-radioactive Mn(II) at sufficient concentrations to generate T1weighted MR contrast and radiotracer concentrations of

52

Mn for generating PET signal. The

phantom images from both short and long TI also provide examples of positive and negative MR
signal resulting from different values of TI.
Compounds that can bind paramagnetic cations, such as Mn(II) (Section 1.2.3), hold
potential for dual-modality PET/MR imaging if they can be radiolabelled with a radiotracer of
the same cation. In unpublished results from collaborators at another institution, a compound has
demonstrated the ability to bind manganese for potential MEMRI applications. In future work,
we will endeavor to radiolabel this compound with 52Mn for potential PET/MR imaging studies.
This radiolabelling will be carried out by altering pH, confirmed by radio-HPLC, and applied to
PET/MR imaging, first in phantom studies. Just as we demonstrated with our PET/MR imaging
of free Mn(II)/52Mn in solution in a phantom, any platform for a PET/MR contrast agent would
require many times more atoms of non-radioactive metal compared to its PET radioisotope(s)
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because PET inherently has much better sensitivity to PET radiotracers than MRI does to
contrast agents for that modality.

4.5. Conclusions and Recommendations
•

A

phantom

containing

various

concentrations

of

non-radioactive

Mn(II)Cl2·(H2O)4 dissolved in water ,was imaged by MRI using an inversion
recovery pulse sequence. The signal from the images were analyzed, and these
results were used to calculate the relaxivity of this compound in aqueous
solution.
•

Another phantom was constructed that contained a matrix of different
concentrations of non-radioactive Mn(II)Cl2·(H2O)4 dissolved in water to
which different amounts of 52Mn had been added. This phantom was imaged
by PET/MR and revealed changes in both MR and PET signals.

•

Recommended future directions: Investigate the utility of

52

Mn by

radiolabeling a compound that has been used to chelate Mn(II) for MRI
imaging; perform PET/MR imaging of phantoms containing the compound
complexed with non-radioactive Mn(II) and radioactive

52

Mn(II) in various

concentrations and radioactivities.
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Chapter 5. Remotely-Controlled Modules for
the Isolation of PET Radiometals1,2,3,4
This chapter describes purification modules that were designed, constructed, and wired
for being controlled remotely by software running on a laptop. These modules are useful for
isolating the product radionuclide from a bombarded solid target because the module can be
placed inside of a lead hot cell, where the separation processes can be carried out. The user
1
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Wooten, A.L.; Schweitzer, G.D.; Lawrence, L.A.; Madrid, E.; Lapi, S.E., 2012. An automated
system for production of 89Zr. AIP Conf. Proc. 1509, 201-205. 14th International
Workshop on Targetry and Target Chemistry, Playa del Carmen, Mexico, 26-29 Aug.
2012.
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2

A.L.W. contributed to the following aspects of projects in this chapter. For the 89Zr module: module assembly,
module installation inside hot cell, test productions of 89Zr. For the 86Y module: ordering and assembling
components, electrical wiring, installation of module into hot cell, cold testing of module. For the 52Mn
module: design. For all modules: writing and preparation of figures and tables.

3

Project acknowledgments: The authors for the manuscripts mentioned above have contributed to design of the
modules, assembly and automation of the modules, testing the modules with non-radioactive and
radioactive materials. In particular, G.D.S. designed and assembled much of the 89Zr module and
participated in validation of the module; all LabVIEW programming for the 89Zr and 86Y modules was
performed by L.A.L. (WUSM/MIR); most of the electronics were designed and installed by L.A.L.; and E.
Madrid, E. Mebrahtu, and D.H.S. of the isotope production team (WUSM/MIR) have contributed to data
from repeated productions during scaling up the levels of radioactivity and during routine production of
isotopes. E. Mebrahtu performed much of the DFO titrations.

The authors acknowledge G.G. Gaehle (WUSM/MIR) for advice in designing automated modules; W.H. Margenau
(WUSM/MIR) and J.W. Linders (Dept. of Chemistry, WUSTL) for constructing certain components of the
systems; J.W. Linders and the WUSM Instrument Machine Shop for machining the Niobium target holders;
G.G. Gaehle, W.H. Margenau, and P.M. Margenau (WUSM/MIR) for operation and maintenance of the
cyclotron; and O.F. Ikotun (Lapi group) and B.V. Marquez (Lapi group) for general advice on 89Zr
separation chemistry and DFO titration.
4

Project-specific funding: This work was funded by the United States Department of Energy, Office of Science,
Nuclear Physics Isotope Program under grant DESC0008657.

controls the module from outside the hot cell and thus receives significantly diminished radiation
dose. Additionally, utilizing automated modules for separations can reduce opportunities for
human error in a separation procedure and even improve the purity of the final product by
reducing exposure to contaminants that may be present in a more open laboratory environment.

5.1. Background
Although the radionuclides and procedures can vary widely, certain design principles for
production modules can be broadly applied. Section 5.1 provides background for the work
presented later in this chapter by first examining other modules that have been published for
production of radionuclides and radiopharmaceuticals. Despite increasing interest in recent years
in using positron-emitting radiometals for pre-clinical and clinical PET imaging research, most
of these isotopes are produced and shipped from only a few centers and companies worldwide.
Consequently, there is not widespread demand for modules capable of producing PET
radiometals. The vast majority of modules developed for production of PET radiometals are
found in research literature, and special attention will be paid here to these examples.
Regardless of the radionuclide or the chemical process implemented, automated modules
are typically designed to operate behind heavy radiation shielding, such as inside a hot cell, for
scaled-up, high radioactivity processes. In addition to the primary objective of radiation
shielding, a hot cell can provide a clean environment that is shielded from airborne contaminants
in the lab, and the hot cell can also include air scrubbing, radiation monitoring, and live video
feed of the module. Figure 5.1 shows examples of hot cells with and without a lead glass
window.
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Figure 5.1. Examples of commercially available hot cell capable of housing and integrating
with automated modules.
A unit by Comecer (Castel Bolognese, Italy) containing two cells, one with a lead glass window,
each containing a module connected by wire to an exterior laptop for monitoring and control. The
top of the unit shows pressure monitors and radiation dose readouts for both cells and a video
monitor for the bottom cell. The interior of these hot cells includes a tray on which to place a
module for remotely-controlled chemistry, a video camera, vapor exhaust, power outlets, a rubber
block of ports for feeding relatively large wires and tubes into the interior of the hot cell, and two
septa for relatively small wires and tubes.

Several modules have been designed for the chemical isolation of PET radiometals.
Production of PET radiometals tends to be centralized at a limited number of production centers
that ship the radionuclides to end users. Thus, the modules that have been developed for
production at these centers have not been imitated widely by other research institutions. In recent
years, interest has increased in using antibodies and nanoparticles as platforms for imaging
contrast agents, and certain positron-emitting radiometals, especially

64

Cu and

89

Zr, have

emerged as valuable radiolabels for these potential agents (Section 1.4.4). Thus, there has been
an increase automation for scaled-up production of 64Cu and 89Zr, and even a few commercially
available modules have become available for these radionuclides. Table 5.1 summarizes a few
published automated modules for the separation of 60,64Cu, 86Y, and 89Zr.
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Table 5.1. Published automated modules for production of 60,64Cu, 86Y, and 89Zr.
Product
Isotope
60/64

Chemical
Form

enriched 64Ni
electroplated onto
Au disc

64

Cu(II)
in 0.5 M HCl

Cu

Separation
Process

Targeta

Anion-exchange chromatography

Reference

(Kume, et al., 2012)

64

Cu(II) in 0.1
M HCl

"
enriched 60/64Ni
electroplated on
Pt surface
enriched 60/61/64Ni
electroplated on
Au surface

60/64

Cu(II)
in 0.5 M HCl
60/61/64

Cu(II)
in 0.5 M HCl
86

89

86

Y(III)
in 3 M HCl

Y

Zr

86

SrCO3 powder

nat

Oxalic acid

Y metal foil

"

(Burke, et al., 2010)

"

(Matarrese, et al., 2010)

"

(Welch, et al., 2006)

Sr-specific resin, Y-specific resin,
cation-exchange resin

(Park, et al., 2004)

Cation-exchange chromatography via
hydroxamate-functionalized resin

(Siikanen, et al., 2012)

a

Description of the portion of the cyclotron target that enters the automated system. (Table from
Wooten, et al., 2013. Table courtesy of MDPI. Creative Commons.)

5.1.1. Production and Applications of 89Zr
The isotope

89

Zr is one of several positron-emitting radiometals that are increasing in

popularity as radiolabels for PET (Anderson and Welch, 1999; Ikotun and Lapi, 2011; Nayak
and Brechbiel, 2009; Wadas, et al., 2010). In particular,

89

Zr holds significant potential as a

radiolabel for antibodies, antibody fragments, and peptides for the in vivo molecular imaging of
antigens using PET (McCabe and Wu, 2010; van Dongen, et al., 2007; van Dongen and Vosjan,
2010; Verel, et al., 2005; Vugts, et al., 2013). Zirconium-89 is well-suited for this technique
because it is a positron-emitter with a half-life that is long enough to accommodate the longer
targeting time and biological half-life for these relatively large imaging agents. So far, the most
prevalent application for

89

Zr has been cancer imaging. The information obtained using PET
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imaging of

89

Zr compounds can be useful for cancer staging, therapy planning, and treatment

monitoring, making 89Zr a potentially valuable tool for personalized cancer care.
There are several properties of

89

Zr that make it an attractive radiolabel for peptides,

antibodies, and nanoparticles. Most importantly, the half-life of

89

Zr (t1/2=3.3 days) is close

enough to the targeting time and biological half-life of antibodies and other macromolecules that
could be used as targeting agents. Additionally, 89Zr emits positrons with a sufficient branching
ratio (Iβ+,total=22.7%) and provides good spatial resolution in PET because it emits positrons at a
low average energy (Eβ+,avg.=396 keV), and therefore a lower positron range (1.2 mm)
(Disselhorst, et al., 2010) compared to several other PET isotopes. Unfortunately, 89Zr also emits
a high-energy (909 keV) gamma ray with a high branching ratio (99.0%), meaning that the dose
rate for this isotope is significant (Γ=6.6 R⋅cm2/mCi⋅h). The decay product of 89Zr (and 89mZr) is
always the stable nuclide

89

Y, so there is no additional dose from daughter nuclei. Figure 5.2

shows a simplified decay scheme for 89Zr.

Figure 5.2. Simplified decay scheme for 89Zr.
(Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons.)
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The vast majority of medical centers capable of producing medical isotopes do so using a
low-energy “biomedical” cyclotron capable of bombarding a target with protons with energy (Ep)
<20 MeV (and alternatively deuterons with energy (Ed) <10 MeV). For these particles and
energies, the highest cross-section is the (p,n) reaction with a peak cross-section of ~0.8 b at
Ep~14 MeV. The (p,n) reaction uses

nat

Y target material, which is monoisotopic as 89Y and thus

relatively inexpensive. For the above reasons, the

nat

Y(p,n)89Zr reaction is the most common

reaction route for 89Zr production (Kasbollah, et al., 2013). However, contaminants can also be
produced in a

nat

Y foil via the following common proton reactions: (p,n)89mZr, (p,2n)88Zr,

(p,pn)88Y. Fortunately, high radionuclidic purity can still be achieved using ~15 MeV protons
because

89m

Zr has a short half-life (t1/2 = 4.2 m) and a high degree of isomeric transition (IT =

93.8%) and because the (p,2n) and (p,pn) reactions require greater proton beam energies, so they
have low cross-sections at Ep~15 MeV—less than 0.2 and 0.02 b, respectively
(BNL/NNDC/CSISRS). Figure 5.3 shows plotted cross-section data for reactions that are
relevant to bombardment of

nat

Y with low-energy protons: (p,n)89gZr, (p,n)89mZr, (p,2n)88Zr, and

(p,pn)88Y, and the important characteristics of

89

Table 5.2.
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Zr production in general are summarized in

Figure 5.3. Screen shot of published cross-section data for reactions relevant to
bombardment of natY with low-energy protons.
Screenshot of nuclear reaction cross-section data that were accessed via
NRDC/BNL/NNDC/CSISRS and plotted using the X4-Servlet from BNL/NNDC. (Data accessed
via: NRDC/BNL/NNDC/CSISRS; Otuka, et al., 2014; Zerkin, 2015.)

Table 5.2. Summary of characteristics for production of 89Zr using a low-energy cyclotron.
Target (natural abundance)

nat

(100% 89Y)

Production reaction

(p,n)89Zr

Y

(t1/2 = 3.27 days)

Reaction threshold

3.7 MeV

Stopping range of 14.7 MeV protons

1.02 mm
(p,n)89mZr

Other possible reactions

(t1/2 = 83.4 days)

88

(t1/2 = 107 days)

(p,2n) Zr
(p,pn) Y
Optimum beam energy, Ep

(t1/2 = 4.2 m)

88

13 MeV
hot-rolled natY metal foil

Target preparation

Optimum beam energy was selected to avoid production of 88Zr contaminant, while still producing
89
Zr. (Table from: Wooten, et al., 2013. Table courtesy of MDPI. Creative Commons.)
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Out of several papers that we examined for using the (p,n) reaction for

89

Zr production

and isolation, five used Y foil targets (Dejesus and Nickles, 1990; Dutta, et al., 2009; Holland, et
al., 2009; Link, et al., 1986; Walther, et al., 2011), two used sputtered Y onto Cu (Meijs, et al.,
1994; Verel, et al., 2003), and one used Y2O3 pellets (Kandil, et al., 2008). Although the
sputtered targets provided superior heat transfer and therefore allowed for higher beam currents,
we chose to use Y foil for ease of use. For a hypothetical irradiated Y foil that contains 100 mCi
of 89Zr, <0.3 µg of 89Zr atoms are present in the foil, and these product atoms must be extracted
chemically to give the desired product—a solution containing

89

Zr(IV) ions. So far, the most

prevalent chelator of the 89Zr(IV) cation is desferrioxamine (DFO) (Deri, et al., 2013; Meijs, et
al., 1992). This separation has been performed with mixed results using several different
techniques (Holland, et al., 2009), including solvent extraction (Dejesus and Nickles, 1990;
Dutta, et al., 2009; Kandil, et al., 2008; Lahiri, et al., 1997; Link, et al., 1986), cation-exchange
(Dutta, et al., 2009; Kandil, et al., 2008), anion-exchange (Dejesus and Nickles, 1990; Kandil, et
al., 2008; Link, et al., 1986; Zweit, et al., 1991), and solid hydroxamate resin (Fadeeva, et al.,
1989; Herscheid, et al., 1983; Holland, et al., 2009; Meijs, et al., 1994; Verel, et al., 2003).
Hydroxamate resin separation has emerged as the preferred method following the publication of a
standardized method for producing and separating 89Zr by Holland, et al. (Holland, et al., 2009). This
separation can produce high recovery, radionuclidic purity, and effective specific activity (ESA).
Our objective for this work was to automate the process that was reported by Holland, et al.
(2009) based on chemistry that was developed by Verel, et al. (2003), Meijs, et al. (1994), and
Herscheid, et al. (1983).
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5.1.2. Production and Applications of 86Y
Yttrium-86 is a medically important radioisotope for imaging by positron emission
tomography (PET) because of favorable decay characteristics, amenability to radiolabelling, and
because it has identical chemistry to
properties of

86

90

Y, a therapeutic radioisotope. The nuclear decay

Y are summarized in Table 5.3. Yttrium-86 emits positrons at a low enough

average energy (Eβ+,avg=660 keV) for acceptable spatial resolution in PET and with a total
positron branching ratio (Iβ+,total=31.9%) that is greater than the PET radiometals

64

Cu and

89

Zr

(ENSDF/NNDC/BNL, 2015), providing more signal per radioactivity. The half-life (t1/2=14.7
hours) for

86

Y is similar to the biological half-lives of peptides and antibodies, and it can be

attached to these molecules with numerous bifunctional chelators, including derivatives of
DTPA, DOTA, EDTA, NOTA, and TETA (Ikotun and Lapi, 2011; Wadas, et al., 2010; Nayak
and Brechbiel, 2009). This capability makes 86Y a suitable radiolabel for nuclear imaging of the
biodistribution of these targeting molecules, along with

64

Cu,

89

Zr, and other radionuclides

(Ikotun and Lapi, 2011; Nayak and Brechbiel, 2009). Additionally,

86

Y-PET can be applied to

new molecules because chelating molecules, including derivatives of DOTA and DTPA, have
proven useful for radiolabelling with

86

Y and

90

Y. This includes the FDA-approved

radioimmunotherapy drug, Zevalin® (ibritumomab tiuxetan; Spectrum Pharmaceuticals,
Henderson, Nevada, United States), which consists of a monoclonal antibody labeled with
chelated in a derivative of DTPA.
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90

Y

Table 5.3. Summary of chemical and nuclear decay properties of 86Y with a simplified decay
scheme.
Half-life, t1/2
Daughter isotope
Decay modes
β+ energy, !!!,!"#
γ-ray energy, Eγ (intensity)
Gamma factora, Γ
Theoretical specific activity
Metastable isomer(s)

14.74 hours
100% 86Sr (stable)
32% β+
68% EC
660 keV
1077 keV (82.5%)
18.9 R·cm2·mCi-1·h-1
212.53 Ci·µmol-1
86m
Y

(Data: BNL/NNDC/ENSDF; aSmith and Stabin, 2012.)

In Zevalin and other applications of
imageable surrogate for

90

90

Y, the radioisotope

111

In is often used as an

Y by single photon emission computed tomography (SPECT) for

determining distribution and dosimetry. However, this approach suffers the limitations of SPECT
with respect to spatial resolution and calculating dosimetry, and indium does not have exactly the
same chemistry as yttrium, which would affect labeling efficiency and stability, as well as the in
vivo distribution of any ions that might become de-complexed. Furthermore, different metal
radiolabels, even while still chelated and bound to a peptide or antibody, can affect in vivo
distribution. Yttrium-86 is attractive as a surrogate for 90Y because it has identical chemistry to
90

Y and is imageable by PET, which has better spatial resolution than SPECT and is inherently

quantitative for more accurate dosimetry calculations for 90Y. Table 5.3 summarizes the nuclear
decay and chemical properties of 86Y.
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Figure 5.4. Cross-sections for the production of 86,86mY via bombardment of 86Sr with lowenergy protons.
Screenshot of nuclear reaction cross-section data that were accessed via
NRDC/BNL/NNDC/CSISRS and plotted using the X4-Servlet from BNL/NNDC. (Data accessed
via: NRDC/BNL/NNDC/CSISRS; Otuka, et al., 2014; Zerkin, 2015.)

Many PET centers that produce medical isotopes from cyclotron bombardment do so
using low-energy medical cyclotrons with proton energies (Ep) <20 MeV. At these energies, the
most practical way to produce 86Y by proton bombardment would be via the 86Sr(p,n) reaction,
which produces
86m

86

Y with a maximum cross-section (σmax) of ~0.7-0.8 b at Ep~11-15 MeV and

Y with σmax~0.3 b at Ep~14-15 MeV (Figure 5.4). Furthermore,

86m

Y has a relatively short

half-life (t1/2=48 min.) and undergoes isomeric transition to 86Y with a branching ratio >99.3%,
so it contributes significantly to production of ground-state 86Y and is therefore not considered a
contaminant for

86

Y production. Since strontium has four stable isotopes and

naturally abundant, it is preferable to bombard an enriched

86

86

Sr is only 9.9%

Sr target, to reduce production of

radiocontaminants from other isotopes of Sr in the target, such as 85,85m,87,88Y, 84Rb, and 85Sr, all
of which have t1/2>1 h, as well as σ<0.1 b at Ep<20 MeV. Based on cross-section data, we
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expected contamination from some of these products even with a perfectly enriched target, yet
we only observed contamination from

87,88

Y, which we believed resulted from enrichment

<100% (see Results and Discussion). Since strontium is not stable in ambient conditions, several
published studies used commercially available 86SrCO3 powder as a target material, while Yoo et
al. converted

86

SrCO3 to

86

SrO by thermal decomposition. In addition to having a greater

percentage of 86Sr by total mass than 86SrCO3, they observed that 86SrO tolerated higher proton
beam currents because of better thermal conductivity. In this work, we have designed, built, and
commissioned a module that has performed the separation of 86Y safely and routinely.

5.2. Experimental
5.2.1. Materials
Natural yttrium foil was purchased from Alfa Aesar (Ward Hill, Massachusetts, United
States), and niobium and platinum metals were purchased in rod form from A.D. Mackay
(currently in Denver, North Carolina, United States). A silica-based weak cation-exchange resin
was purchased from Waters (Milford, Massachusetts). The chelator DFO-NCS was purchased
from Macrocyclics (Dallas, Texas, United States). Ultrapure (~18 MΩ) water was purified in a
Millipore system (Billerica, Massachusetts) and was used for all other purposes, including
cleaning the automated modules before each use and making solutions for DFO titrations.
[86Sr]SrCO3 was purchased from Isoflex (San Francisco, California, United States). All other
chemicals were purchased from Sigma-Aldrich (Saint Louis).
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5.2.2. Cyclotron Production
5.2.2.1. Cyclotron Production of 89Zr
Discs with diameter 9.5 mm were punched from 0.64 mm thick natY foil (disc mass ~0.2
g). Niobium metal target holders were machined, consisting of a base and a screw-on lid with a
centered, circular hole to expose the target foil to the cyclotron beam. Niobium was selected
because of its high melting temperature (Tm = 2,468 °C) and high chemical inertness
(Greenwood and Earnshaw, 1997). A single

nat

Y disc was placed inside the target holder, as

shown in Figure 5.5. Due to activation, many target holders were machined to allow residual
activity to decay before reuse. Before each target holder was reused, it was scrubbed by hand
using a cotton swab dipped into a slurry made from Al2O3 powder and water. The target holder
was placed in 6 M HCl for 1–4 h for cleaning and dried in an oven. The target assembly was
mounted in the CS-15 cyclotron (The Cyclotron Corporation, Berkeley, California, United
States) at the Mallinckrodt Institute of Radiology (MIR) at Washington University in Saint Louis
School of Medicine (WUSM) and bombarded with protons (Ep ≈ 14.7 MeV) to produce 89Zr via
the

nat

Y(p,n)89Zr reaction. The beam exit energy was Ep ≈ 7.9 MeV, based on calculations

performed using The Stopping Range of Ions in Matter (SRIM) software (Ziegler, et al., 2010),
which implements the Bethe formula for stopping power. After Ep was degraded by the Y foil,
the beam stopped in the base of the Niobium target holder, as calculated with Transport of Ions
in Matter (TRIM) module within the SRIM package. During bombardment, the target holder
assembly was cooled on the beam side by a He gas jet and on the reverse side by flowing chilled
water (T ≈ 2.2 °C). Following irradiation, the target remained in the solid target station for a few
hours to allow for the decay of short-lived contaminants, especially 89mZr in the Y foil. Then, the
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target assembly was removed by hand, and other short-lived contaminants were allowed to decay
overnight while the target was in a shielded location. On the following morning, chemical
separation was performed in the hot cell that contained the automated module.

Figure 5.5. Photograph of the disassembled (left) and assembled (right) Y foil target and
Niobium target holder.
(The samples on the left and right sides of the arrow above are photographs of representative
samples, and they may not necessarily be the exact same samples.) (Image: Wooten, et al., 2013.
Image courtesy of MDPI. Creative Commons.)

5.2.2.2. Cyclotron Production of 86Y
The bare metal strontium is very chemically reactive due to rapid oxidation by air and
reactivity with water, which produce strontium oxide and strontium hydroxide, respectively. Due
to this reactivity, 86SrCO3 was used as the initial material. 86SrCO3 was heated at 1000-1100°C
for 4-12 hours under Ar gas to produce

86

SrO, which was immediately stored in an evacuated

vessel to prevent the spontaneous conversion back to 86SrCO3 in air. The 86SrO was preferred to
86

SrCO3 because Yoo, et al. (2005) noted that

86

86

SrCO3 and observed experimentally that, relative to

SrO had a higher content of Sr per mass than
86

SrCO3,

86

SrO could withstand greater

beam current (6 vs. 2 µA) and could improve production yields of 86Y (4.5 vs. 2.3 mCi·uA-1·h-1).
Shortly before the start of cyclotron bombardment, the

86

SrO was compressed under 3,000 psi

using a pneumatic press into a powder target holder made of platinum. The target holder
consisted of a single piece of platinum, cut into a disk that fit into the solid target end station of
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the cyclotron, with a dimple at the center cross hatched to improve the adhesion to the target
material. The thickness of the compressed target is difficult to accurately measure, but assuming
the powder is perfectly compressed, we estimated the target thickness to be ! = 4! !! ! ! = 1.16
mm where m is the mass of the powder, d is the diameter of the cavity, and ρ is the density of the
salt. The target was mounted in the CS-15 cyclotron (The Cyclotron Corporation, Berkeley) at
the Mallinckrodt Institute of Radiology (MIR) and bombarded with protons to produce

86

Y via

the 86Sr(p,n)86Y reaction.

5.2.3. Separation Chemistry
5.2.3.1. Separation Chemistry for 89Zr
Figure 5.6 summarizes the general steps in our production process. A stock of
hydroxamate resin was made by functionalizing the weak cation-exchange resin with
hydroxamate groups according to a procedure published in Holland, et al. (Holland, et al., 2009),
based on chemistry developed by others (Herscheid, et al., 1983; Meijs, et al., 1994; Verel, et al.,
2003). Chemical separation of

89

Zr from the

nat

Y foil was performed in an in-house built

automated module installed inside a lead hot cell (Comecer, Castel Bolognese, Italy), typically
on the day after bombardment. During setup for each separation of 89Zr, 100 mg of hydroxamate
resin from this stock was loaded between two polyethylene (PE) frits (Grace, Deerfield, Illinois,
United States), which were between two small pieces of glass wool, and loaded into a customblown glass column reservoir that was then incorporated into the system with air-tight
connections. The entire irradiated target assembly—target holder and target foil—was quickly
dropped into a Teflon dissolution vessel mounted on the automated system. This transfer was
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performed manually, the door to the hot cell was then closed, and the remaining steps in the
purification process were performed remotely.

Figure 5.6. A flowchart describing the process for production and isolation of 89Zr from an
irradiated Y foil.
Solid line: automated steps; dashed line: steps that were performed manually. (Image: Wooten, et
al., 2013. Image courtesy of MDPI. Creative Commons.)

Using a custom software program that was made in the LabVIEW platform (National
Instruments, Austin, Texas, United States) running on a laptop outside the hot cell (Figure 5.10),
10 mL 2 M HCl was added to the dissolution vessel to dissolve the natY target. After waiting ~1 h
for complete dissolution, the dissolved target was transferred to the column through tubing using
compressed air. Then, the Y was eluted from the column in 10 mL 2 M HCl and collected in a
waste vial, leaving the

89

Zr bound on the column. The column was rinsed with 10 mL water,

which was collected in the same waste vial, and then the 89Zr was eluted in 1 mL 1 M oxalic acid
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and collected in a product vial as 89Zr chelated by the oxalate ions (89Zr-oxalate). Although other
studies have achieved greater recovery and activity per volume by collecting multiple fractions
from the column (Holland, et al., 2009; Meijs, et al., 1994; Verel, et al., 2003), we currently have
automated the collection for only one elution of the product for simplicity in the automated
module. However, to compensate for collecting a single fraction, we increased slightly the
volume of eluent to 1 mL. After collection of 89Zr in the product vial, the product was retrieved
from the hot cell manually and then dispensed in 2 mL skirted microcentifuge tubes for
distribution within our institution and/or shipping to extramural researchers.

5.2.3.2. Separation Chemistry for 86Y
A procedure for the chemical separation of

86

Y from

86

Sr was adapted from Avila-

Rodriguez, et al. (2008) and is summarized in Figure 5.7. The separation was performed in an inhouse built automated module installed inside a lead hot cell (Comecer, Castel Bolognese, Italy),
typically a few hours after bombardment, to allow for the short lived 86mY to decay. During setup
for each separation of 86Y, new solutions were loaded into the source vials and a new filter was
placed over the glass frit of the separation column. The irradiated target was quickly dropped
into the Teflon dissolution vessel mounted on the automated system. This was done manually,
the door to the hot cell was then closed, and the remaining steps of purification performed
remotely.
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Figure 5.7. A flowchart that describes the process for the production and chemical
separation of 86Y from an irradiated SrO target.
Dashed boxes indicate steps that were performed manually, solid boxes are automated steps.

A custom software program made in the LabVIEW platform was run on a laptop outside
the hot cell to control the release of chemicals and transfer of material remotely. A volume of 3
mL of 6 M HCl was added to the dissolution vessel to dissolve the SrO target. After waiting ~5
min. for removal of the SrO powder from the target holder, 12 mL of 8 M NH4OH was added.
The colloidal solution was transferred to the 0.45 µM filter through tubing using compressed air.
The [86Sr]Sr(OH)2 passed through the filter. The first Sr fraction was collected. 2 x 12 mL of
basic MilliQ water was passed to the dissolution vessel then the filter and extracted as a wash. A
volume of 2 mL of 1 M HCl was slowly passed over the filter and the 86Y product was collected.
The product was brought to dryness at 130 °C under Ar gas.
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5.2.4. Automated Module
5.2.4.1. Automated Module for 89Zr
The path of fluids (liquids and air) through the system was controlled by solenoidactuated isolation valves, and, as a fail-safe, solenoid-actuated pinch valves prevented liquids
from flowing through the flexible tubing at inappropriate times or in the opposite direction.
Solenoid valves were manufactured by NResearch (West Caldwell, New Jersey, United States).
Solvents only came in contact with polymers and glass in the system. The compressed air was
adjusted by a pressure regulator (Swagelok). The flow of compressed air was precisely
controlled by a hot wire digital mass flow controller (Pneutronics) that received commands from
the computer. Before each separation, all liquid solvents were pre-loaded into the system by hand
in glass vials capped with silicone rubber septa that allowed for insertion of two PEEK needles—
one connected to compressed air and one for transporting the liquid. The vials were then clipped
onto the front of the module, and during the separation each liquid was extracted from its vial
using positive pressure from the PEEK needle that was connected to compressed air. The general
schematic of the entire system is shown in Figure 5.8.
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Figure 5.8. Process flow diagram for the automated module used for chemical separation of
89
Zr from irradiated natY foils.
CAP: compressed air pump; CV: check valve; HV: hand valve; MFC: mass flow controller; NC:
normally closed; NO: normally open; R: radiation detector; RV: regulator valve; SI: solenoid
isolation; SP: solenoid pinch; V: valve. Valves enclosed by a dashed box are part of a gradient
manifold. Valves V14, V18, and V19 do not exist in the actual system, so they are not displayed
here. (Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons. Original image
was made using Edraw Max software (EdrawSoft, Sheung Wan, Hong Kong).)

An automated module was designed and built to perform a

89

Zr- separation protocol

remotely inside a lead hot cell. The frame for this module (h × w × d = 21 × 18 × 11 in. = 0.53 ×
0.46 × 0.28 m) was constructed of extruded aluminum modular framing, to which walls were
attached that were made of ultra high-molecular weight polyethylene. Various system
components were mounted on these plastic walls, as pictured in Figure 5.9. The front panel of
the module was hinged to allow easy access to the components and wiring inside the module. All
liquids were pushed through the system by compressed air through flexible tubing. All liquid and
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most gas connections were assembled using non-metallic connectors, which reduced exposure to
metal contaminants. Many of the liquid connection pieces were designed for high-pressure liquid
chromatography (HPLC) systems and were made of ethylene-tetrafluoroethylene (ETFE,
Tefzel®); gas connections were made using stainless steel Swagelok® tube fittings (Swagelok,
Solon, Ohio, United States).

Figure 5.9. Photograph of the module for isolating 89Zr from natY metal target material.
The entire target holder assembly was placed in the dissolution vessel after bombardment, the natY
target material itself was dissolved and transferred to the column for immobilization of the 89Zr,
leaving behind the Niobium target holder in the dissolution vessel. (Image: Wooten, et al., 2013.
Image courtesy of MDPI. Creative Commons.)
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A computer located outside of the hot cell was used to control the entire chemical
separation process. A program was created on the LabVIEW platform that featured a graphical
user interface (GUI) that provides instructions and controls for production personnel. Users could
follow a step-by-step procedure with a pre-programmed control scheme and, if necessary,
intervene by controlling individual valves in the event of a problem in the system. Using the
GUI, the user can easily and precisely change the flow through the mass flow controller and
thereby the speed at which liquids were pushed through the system, most importantly the speed
of solvents through the column. We found that to improve recovery, the final eluent was allowed
to sit on the column for ~20 min. and then slowly pushed through the column at ~0.2–1 mL/min.
The GUI also included a live video feed from a mini color camera (ApexCCTV, Allen, Texas,
United States) providing an up-close view of the liquid on the column, as well as real-time
graphs that reported the radiation dose measured by four Si PIN-type photodiode detectors
(Carroll & Ramsey, Berkeley, California, United States). These detectors were strategically
placed close to the dissolution vessel, resin column, waste vial, and product vial (see Figure 5.8),
allowing the user to monitor the movement of radioactivity through the system in real time. A
screenshot of the GUI near the end of a separation process is shown in Figure 5.10.
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Figure 5.10. Screenshot of the window containing the graphical user interface (GUI) that
was used to control the automated module.
(Image: Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons. Program was created
in the LabVIEW platform (National Instruments, Austin, Texas, United States). Programming
performed by L.A. Lawrence.)

5.2.4.2. Automated Module for 86Y
An automated module was designed and built to perform the separation of

86

Y and Sr

inside of a lead hot cell. Madrid, et al. (2011) had previously developed a semi-automated
module for the remote isolation of

86

Y at WUSM/MIR, and we benefited from the experience

gained in producing that module and utilizing it for isolation of

86

Y; however, a newer

replacement module was needed. The walls of the module were of ultra-high-molecular weight
polyethylene, and most components were mounted onto these plastic walls. The front wall of the
module was hinged to allow easy access to wiring and internal components. Figure 5.11 shows a
process flow diagram for the system. Vacuum from a Venturi pump was used to pull all liquids
through the system through flexible tubing and through narrow needles made in-house from
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polyetheretherketone (PEEK™) tubing. The Venturi pump was powered by compressed air from
the building and the speed of liquids through the system was controlled by pulsing valves open
and closed during a step in the process—instead of leaving them open continuously during the
step for maximum speed of liquids. Solenoid-actuated isolation valves were used to control the
path of liquids and gases through the system, and, as a fail-safe, solenoid-actuated pinch valves
were used, to prevent liquids from flowing through tubing in the wrong direction or at incorrect
times. Solenoid valves were manufactured by NResearch. A hand valve adjusted the compressed
air that entered the system from the building supply. To reduce risk of metal contaminants,
solvents only came in contact with polymers and glass in the system, and no metal components.
All liquid solvents were pre-loaded into the system before each separation by hand in glass Vbottom vials, each capped with a lid that included a silicone rubber septa, which allowed for the
insertion of PEEK needles for transporting air, vacuum, or liquids. The vials were clipped onto
the front of the module, as seen in Figure 5.12. Each liquid was extracted from its vial by
vacuum, necessitating vents on each input vial (Figure 5.11).
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Figure 5.11. Process flow diagram for the automated module used for chemical separation of
86
Y from irradiated SrO powder targets.
CAP: compressed air pump; CV: check valve; HV: hand valve; NC: normally closed; NO:
normally open; PT: pressure transducer; R: radiation detector; SI: solenoid isolation; SP: solenoid
pinch; V: valve; VP: venture pump; double line: PTFE tubing for compressed air or vent only;
triple line: PTFE tubing for Ar gas only. Valves enclosed by a dashed box are part of a gradient
manifold. Not pictured: manometer. (Image was made using Edraw Max software (EdrawSoft,
Sheung Wan, Hong Kong).)
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Figure 5.12. A photograph of the automated module for 86Y.

To control the components of the module, a custom program was created in LabVIEW.
This program included a GUI that provided instructions and controls for production personnel, as
shown in screenshots in Figure 5.13. The computer followed a pre-programmed control scheme,
that, if necessary, could be overridden to control individual valves in the event of a problem in
the isolation process. The GUI also included a live video feed from mini color cameras
(ApexCCTV), which provided up-close view of liquid at selected points in the system, such as,
in Figure 5.13, the liquid passing onto the filter and the liquids flowing into output vials. Silicone
PIN-type photodiode detectors (Carroll & Ramsey) can feed data to graphs in the GUI (Figure
5.13) to monitor the movement of radiation through the system, which is important information
that is complementary to the visual movement of liquids provided by the video cameras.
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Figure 5.13. Screenshot of the window containing the graphical user interface (GUI) that
controlled the automated module.
(Program was created in the LabVIEW platform (National Instruments, Austin, Texas, United
States). Programming performed by L.A. Lawrence.)
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5.2.4.3. Design of Automated Module for 52Mn
As described in Chapter 2, we chose to bombard non-enriched, electroplated chromium
(natCr) because of reduced cost of material and the ability to produce batches of foil discs in an
industrial hard chrome electroplating bath. These foils were held in a Niobium metal target
holder with a screw-on lid that had an open window for the beam to pass through.

nat

Cr foils

were bombarded with ~13.5 MeV protons from the CS-15 cyclotron at WUSM/MIR. In test
separations performed by hand, and following the selected method from Graves, et al., the
bombarded foil was digested in HCl, then ethanol was added before the solution was passed
through a 100-300 mg column of AG 1-X8 resin, an anion-exchange resin. Under these
conditions of that procedure, Cr(III) was eluted, while 52Mn(II) was immobilized on the column.
Manganese-52(II) was eluted in 1 M HCl, dried down, re-dissolved in concentrated HCl, and
then ethanol was added to return the activity to the previous conditions. The column was rinsed
thoroughly with 2 M HCl, 6 M HCl, water, and then the ethanol/HCl mixture to restore it to its
original condition. This separation procedure was repeated two more times, reusing the same
resin each time. This procedure is summarized in Section 2.2.5.2, and a module was designed to
automate this separation process.
The result for this section was a process flow diagram for an automated module that will
be constructed in the future. This diagram is shown in Figure 5.14, and, once it is constructed,
this will be controlled by a LabVIEW program running on a laptop, similar to the programs for
controlling the modules for 89Zr and 86Y (Sections 5.2.4.1 and 5.2.4.2). This program will control
all of the electric solenoid-actuated valves and valve manifolds in the system, which will
determine the movement of liquids to various destinations in the system. This entire process will
be monitored in real time by observing the transport of liquids with small digital cameras and the
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transport of radioactivity with small semiconductor radiation detectors. The necessary
combinations of valve openings and closings will be pre-programmed into a step-by-step
sequence in the LabVIEW program, while retaining the capability to actuate any individual
component at any time simply by clicking its corresponding button. This capability is important
for reacting to unexpected situations that can occur with routine productions. To reduce risks of
liquid leaks associated with pushing liquids using air at positive pressure, this module is
designed to transport liquids that are pulled through the system by vacuum, similar to the

86

Y

module (Section 5.2.4.2). The vacuum is generated by a Venturi pump that using a stream of
compressed air originating from a source external to the module and hot cell. A digital MFC
controlled by the LabVIEW program can control the flow rate of compressed air before the
Venturi pump, thereby controlling the strength of the vacuum.

5.2.5. Product Characterization
The

89

Zr product was characterized for activity amount, radionuclidic purity, and ESA.

The amount of activity that was recovered was measured using a dose calibrator (Capintec,
Ramsey, New Jersey, United States). The radionuclidic purity was characterized using a highpurity germanium (HPGe) detector (Canberra, Meriden, Connecticut, United States). The
product was diluted into a 2 mL skirted microcentrifuge tube, and a 10 min scan of the product
was performed within one half-life of the original bombardment. To search for longer-lived
contaminants, an aliquot of one production was allowed to decay for ~3 half-lives and then
scanned for 12 hours. Gamma ray peaks were identified based on characteristic gamma-rays. Per
Holland, et al. (2009), DFO titration was used to determine ESA, which is the radioactivity of the
product isotope per total amount of metals in the product. To minimize non-specific binding of
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other metals by the DFO, the DFO was challenged by 50 mM DTPA. The titration was carried
out by thin layer chromatography (TLC) on pure cellulose blotting paper that was developed in
50 mM DTPA and scanned using a radio-TLC scanner (Bioscan, Washington, D.C., United
States). At this point, the productions of

86

Y were mainly characterized by radioactivity as

measured by an ionization dose calibrator.

Figure 5.14. Process flow diagram for a module for the isolation of 52Mn from Cr metal.

The final product was characterized for activity amount and radionuclidic purity. A dose
calibrator (Capintec) was used to measure the amount of activity recovered. To characterize
radionuclidic purity, the product was diluted in 2 mL skirted microcentrifuge tubes and scanned
for 10 m, within one half-life of EOB, with a high-purity Ge detector (Canberra) connected to a
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digital spectrum analyzer (Canberra). The samples were allowed to decay for ~3 half-lives and
then scanned for 12 hours, to detect longer-lived contaminants.

5.3. Results
5.3.1. Results from Production of 89Zr
The methods described in this work have been used successfully for several years for the
cyclotron production and chemical separation of

89

Zr. Typically, after the chemical separation

was completed using the automated module, a dose calibrator was used to measure the activity of
89

Zr collected in the product and waste vials. To reduce radiation dose, the system was allowed

to decay for one week before measuring the dissolution vessel, which still contained the
irradiated Niobium target holder, and the intact column assembly, which still included the resin,
frits, and glass wool. The radioactivity measured for all four major module components was
decay-corrected to the end-of-bombardment (EOB) time for each production. The decaycorrected activities were summed to give an estimated total radioactivity of

89

Zr produced in

each cyclotron bombardment. This estimate neglects any activity that was lost in tubing, valves,
etc., but it allows us to compare the performance of the automated chemical separation for
productions with different starting activities. The majority (74%±16%) of 89Zr was collected in
the product vial and the largest loss of activity was to the column (18%±15%), which was greater
than either the waste vial (4%±10%) or the dissolution vessel (3%±3%), as shown in Figure 5.15.
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Figure 5.15. Distribution of 89Zr in various components after each production.
For each production, the activity in each of the four primary system components was decaycorrected to a common time point (end-of-bombardment in the cyclotron) and calculated as a
percentage of the total activity. Displayed here are the average percentages for each component ±
1 SD. N = 14. DV: radioactivity remaining in the dissolution vessel after isolation process. (Image:
Wooten, et al., 2013. Image courtesy of MDPI. Creative Commons.)

The percentage of

89

Zr activity collected in the product vial is the recovery rate of the

chemical separation that was carried out using the automated module and is an important
performance indicator for the separation process. In some cases this may be a result of us only
collecting one elution instead of multiple fractions; otherwise, it may be because the stock of
hydroxamate resin became less effective at binding Zr if it was stored for too long. We chose to
make a stock of the resin for simplicity to avoid functionalizing a new batch of resin for each
production.
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Figure 5.16. Gamma spectra of diluted aliquots from the product vial from two different
productions. DFO-89Zr titration curve that resulted in an effective specific activity of 63
mCi⋅µmol−1 for a selected 89Zr production.
(A) A 10 m scan taken on the same day as chemical separation, and (B) a 12 h scan taken 22 days
after the chemical separation. Eγ: gamma-ray energy; a.u.: arbitrary units. Spectra were zoomed in
on 0 ≤ Eγ ≤ 2,000 keV. Right panel: sigmoidal dose-response curve. DFO titration experiment was
performed by E. Mebrahtu. (Images: Wooten, et al., 2013 (supplementary information). Images
courtesy of MDPI. Creative Commons.)

5.3.2. Results from Production of 86Y
After chemical separation, the 86Y product vial was removed from the hot cell and a dose
calibrator was used to measure the activity of 86Y collected. Before the next 86Y production, the
dissolution vessel, target, filter paper, and Sr fraction were all surveyed in the dose calibrator to
estimate percent recovery. The radioactivity measured for all five components were decaycorrected to the EOB time for each production. The decay-corrected activities were then summed
to give an estimated total radioactivity of

86

Y produced. Before placing the target into the

automated module, the activity of the entire target was measured using a dose calibrator, which
allowed for the percent activity in each component to be calculated. The majority (59%±14%
(not relative uncertainty)) of the

86

Y was collected in the product vial, and the greatest loss of

radioactivity was mainly lost in the elution of Sr (3%±4% (not relative uncertainty)). We found
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that recovery of 86Y was extremely dependent on the type of filter paper used, with the 0.45 µm
mesh providing the best recovery.

80%

% of Total Activity
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Figure 5.17. Distribution of 86Y in various components after each production.

For each production, the radioactivity in the product, waste, and Sr vials, as well as on the
filter, were decay-corrected to a common timepoint and calculated as a percentage of the total
activity. Displayed in Figure 5.17 are the average percentages for each component, with error
bars representing the 2σ (95%) confidence interval. The number of productions (n) represented
by this data was n=11. It should be noted that this production data from using the module for 86Y
should be considered preliminary because it was collected during a phase of troubleshooting and
optimization. Not included in this data were productions in which there was an obvious failure
that resulted in a very large quantity of 86Y not being isolated.
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5.4. Discussion
5.4.1. Automated Module for 89Zr
Automation is an important part of isotope production in particular and nuclear medicine
in general because automated modules enable production centers to separate large activities of
isotopes while still meeting institutional and federal regulations for radiation dose. Several
groups have published on custom-made automated modules for various radiometals, including
64

Cu (Burke, et al., 2010; Kume, et al., 2012; Matarrese, et al., 2010; Welch, et al., 2006),

(Nagatsu, et al., 2011),

99m

Tc (Chattopadhyay, et al., 2012),

86

Y (Park, et al., 2004), and

124
89

I

Zr

(Siikanen, et al., 2012; Wooten, et al., 2012).
The Niobium target holders have been irradiated up to 15 µA without significant
alterations of target or target holder. Since the same beam current, beam energy, and foil
thickness were used for all productions in this work, the bombardment time (tb) was the only
bombardment parameter that was adjusted to control the amount of activity produced in the
cyclotron. The parameters for comparable publications varied widely. Excluding the Y2O3 pellet
targets, only one publication (Dejesus and Nickles, 1990) used a foil that was close to ours in
thickness. Also, the beam current, bombardment time, and µA⋅h all varied widely across
publications. Not surprisingly, the Y2O3 targets used lower currents, presumably because of
reduced heat transfer, while the sputtered targets received high beam current for long
bombardment times.
The predicted activity produced from a cyclotron was calculated by estimating beam
energies at various points in the target using SRIM and calculating the reaction rate between
these points using published empirical cross-section data for the natY(p,n)89Zr reaction (Birattari,
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et al., 1973; Blosser and Handley, 1955; Church and Caretto, 1969; Khandaker, et al., 2012;
Michel, et al., 1997; Saha, et al., 1966; Uddin, et al., 2005). These data were accessed and plotted
through the NNDC online database (NNDC/BNL), as shown in Figure 5.3. We estimated that
37% of the beam was lost in the rim of the lid of the target holder, instead of passing through the
central window to irradiate the exposed

nat

Y foil. The reaction rate (R) was calculated, followed

by the activity (A), using the standard equation for production of a radionuclide: A = R(1−e−λt)
(Ehmann and Vance, 1991), where λ is the decay constant for 89Zr.
To confirm the radionuclidic purity of the solution in the product vial, gamma
spectroscopy was performed. Typically, a short (10 min.) scan of a diluted aliquot from the
product vial was performed on the same day as each chemical separation (Figure 5.16). For one
production, a long (12 h) scan was performed after waiting for several half-lives (~22 days) of
89

Zr to allow it to decay relative to longer-lived potential radiocontaminants, making them easier

to detect by gamma spectroscopy. This spectrum indicated a radionuclidic purity of 89Zr equal to
99.998% of total activity (99.95% of total atoms) and identified

88

Zr as the only

radiocontaminant. Even though our recovery percentage was less than other studies, our
radionuclidic purity was on par with other publications, only one of which had a radionuclidic
purity <99%. This high radionuclidic purity is likely because of the minimal overlap of the
excitation function for the

nat

Y(p,n)89Zr reaction with the

potential reactions. For most productions of

89

nat

Y(p,2n)88Zr reaction, or any other

Zr in this work, ESA was determined by DFO

titration, similar to Holland, et al. (2009). ESA accounts for the presence of any metal isotope
(stable or radioactive) that can be chelated by the selected chelator, in this case, DFO. For each
production, the results of the DFO titration were plotted and fit with a sigmoidal dose-response
curve to produce an EC50 value, which was used to calculate ESA in mCi⋅µmol−1.
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In this work, we present the cyclotron production of

89

Zr using a biomedical cyclotron

and the chemical separation of 89Zr from a Y foil target using an automated module. This module
dissolved the Y foil in acid and then separated the

89

Zr from Y using a hydroxamate resin

column. Our methods reduced radiation dose to production personnel as the separation was
carried out inside a lead hot cell, while the module was controlled by a laptop outside. The
progress of the separation was monitored using radiation detectors in the module, and the final
result for each production was a 89Zr(IV)-oxalate solution, and this solution was characterized for
recovery of activity, radionuclidic purity, and ESA. Our

89

Zr products had very high purity,

similar to other published production methods. The procedures described in this work have been
used for several years to routinely produce

89

Zr for users at our institution and for shipping to

other institutions. Lessons learned from production of 89Zr will be adapted for routine cyclotron
production and chemical separation of other radiometals from solid targets.

5.4.2. Automated Module for 86Y
In this work, we present the cyclotron production of 86Y using a biomedical cyclotron and
the chemical separation of

86

Y from a SrO powder target using an automated module. This

module dissolved the SrO powder in acid and then separated the

86

Y from the Sr by passing

through a filter in a basic solution. The 86Y was then passed through the filter paper using acid
and collected in a separate output vial. Utilizing this automated module for routine production of
86

Y would reduce radiation dose to personnel, as the separation was performed inside a lead hot

cell and controlled remotely by a computer that was located outside of the hot cell. The
separation process was monitored with radiation detectors and cameras positioned on the module
at strategic locations, and the final product for each production was a no-carrier-added solution
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of

86

Y in 1 M HCl. Drying down this product would reduce risk of spills and leaks during

transport, and it could facilitate solvent exchange from 1 M HCl to a different desired solvent.
We do not anticipate that drying down 86Y in 1 M HCl would compromise the solubility of the
86

Y product in water, so we expect that it can be re-dissolved easily.
As mentioned earlier, the production results from the

86

Y module that are presented in

this chapter should be considered preliminary data. Not included in this data were productions in
which there was an obvious failure that resulted in a very large quantity of 86Y not being isolated.
Also, there were many productions in which the pressed powder target did not survive the
cyclotron bombardment, resulting in a target with very little powder remaining in the dish of the
target holder. (Currently, the powder targets for production of 86Y are covered.) The results that
are presented in this dissertation for the semi-automated isolation of 86Y are from relatively early
productions for this new module, which has been used more since those productions were
performed.

5.4.3. Automated Module for 52Mn
52

Mn is an important radioisotope of manganese for studying the chemical behavior of

manganese in many applications. Manganese-52 also has attractive nuclear decay properties that
make it attractive for radiolabelling of agents with long biological half-lives, such as
macromolecules and nanoparticles, because of its long half-life, low positron energy, and
sufficient branching ratio for positron emission. Many methods for isolating

52

Mn from

bombarded chromium target material have been proposed, but a very recent method utilizing a
solution of ethanol and concentrated HCl to elute Cr(III) seems very efficient, robust, and
suitable for automation. Thus, an automated module is a logical and important next step in the
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routine production of 52Mn. Because of the half-life of 52Mn, it is practical to ship it domestically
or even internationally without losing too much of it to decay. Therefore, it is likely that only a
few automated modules will be constructed in the foreseeable future and that these units will be
used to produce large enough batches that can be aliquotted and shipped to meet demand.
As discussed in Chapter 2, scaled-up production of 52Mn can be achieved by bombarding
Cr metal targets that are isotopically enriched 52Cr and/or greater in thickness, increasing proton
energy not beyond ~24 MeV, or bombarding with deuterons in the 40à8 MeV range.
Radiocontaminants co-produced from the latter two solutions would be easily removed by decay
(51,52mMn and 52V) or by chemical isolation of 52Mn from the chromium target material (51Cr).
Manganese-52 emits significant amounts of gamma radiation in addition to its 511 keV
annihilation photons, so radiation safety is a significant issue with this PET radionuclide. Much
study and care is applied to radiation dosimetry for patients receiving injected
radiopharamaceuticals and to limiting exposure for the clinical personnel that administer these
doses as a full-time job. However, it is also important to monitor and limit radiation dose to
personnel responsible for the production of radionuclides and radiopharmaceuticals, especially
since they are likely handling more radioactivity before some of it is lost to nuclear decay and
yield losses from chemical processes. Automated modules are very useful in this respect, both
for isolating radionuclides and synthesis of radiolabelled compounds, because they can be
located inside a hot cell of any size and thickness necessary to protect personnel. The module
that has been designed for the chemical isolation of 52Mn will play an important role in making
this valuable PET radionuclide widely available by enabling routine, scaled-up productions of
much larger activities than would otherwise be reasonable to handle by hand in an open
laboratory benchtop setting, even inside of a lead castle. Based on general experience with
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automated modules for chemical separations of PET radiometals, it is also possible that using
such a module for isolating 52Mn in a hot cell could result in greater purity and consistency by
reducing the influence of human factors and protecting the isolation procedure from
environmental contaminants.

5.5. Conclusions and Recommendations
•

Semi-automated modules for the scaled-up production of

89

Zr and

86

Y were

constructed in collaboration with a team of people. These automated modules
were able to carry out separations inside of a lead hot cell by moving solvents
through tubing by vacuum or compressed air. The separation process was
controlled from outside the hot cell by a laptop that was connected to the
module and running a software program that was produced in-house. The
ability to control separation processes remotely protects production personnel
from significant radiation dose, and these modules have been used routinely to
produce isotopes for use at institutions nationwide, including

89

Zr for a

clinical trial at our institution.
•

We have designed a similar module that will implement the anion-exchange
separation method for 52Mn from a chromium metal target.

•

Recommended future directions: For the

52

Mn automated module: assemble

the module; automate with a custom software program; validate the module
with increasing starting activities until it is ready for routine use; if collecting
the final

52

Mn product in the same glass vessel as the previous rounds
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introduces contaminants in the final product, then a separate line and
collection vessel for the final round of elution of

52

Mn can be added to the

design.
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Chapter 6. Compiled Conclusions and
Recommendations
This dissertation has included concepts and results from applications for positronemitting radiometals, with an emphasis on

52

Mn. These experiments have centered around the

larger ideas that have defined the chapters of this dissertation: radionuclide production and
isolation, biodistribution and PET imaging, applications in PET/MR, and automation for scaledup radionuclide production. The conclusions and recommended future directions for each of
these ideas can be found at the end of each respective chapter, and they are summarized here:

Chapter 1. Introduction
•

Manganese is important because of its natural role as an essential
micronutrient in humans that is involved in several important processes for
life.

•

Manganese has historically caused neurotoxicity when inhaled chronically
from environmental contaminants, and occupational exposure to inhaled
manganese continues to cause neurotoxicity, even in developed countries with
occupational safety measures.

•

Manganese(II) is one of the most highly paramagnetic cations on the periodic
table, which makes it a candidate for the metallic core in T1 contrast agents.
Manganese(II) has very different chemistry, toxicity, and excretion route than
the current standard cation Gd(III), so Mn(II) provides a meaningful
alternative.

•

A radiotracer for the study of manganese is important because of the
sensitivity of many radioactive assays, the ease of quantification, and the
availability of necessary equipment. In vivo imaging of manganese is also
important for studying the above roles of manganese, and PET imaging has
advantages over other nuclear emission imaging modalities (and the lack of a
SPECT radioisotope of manganese).

•

Manganese-52 was selected because it is a positron-emitter with a sufficient
total intensity of positrons, a relatively long half-life for nuclear decay that
would enable studies spanning several days, and the ability to produce

52

Mn

from a non-enriched target bombarded with low-energy protons, which were
available from a cyclotron at our institution. Manganese-52 is a good choice
for studying manganese specifically, but and also has characteristics that make
it competitive with other PET radiometals, such as a very low average
positron energy, which can correspond to good spatial resolution in PET.

Chapter 2. Nuclear Cross-Sections and Chemical Separation of 52Mn
•

Nuclear cross-sections have been measured for the

nat

Cr(p,x)52,52m,54Mn

reactions for incident protons with energy ≤13 MeV, which is easily achieved
by most cyclotrons at medical centers. The cross-section results agreed closely
with theoretical simulations, and they can be used to predict yields of
52,52m,54

Mn when bombarding natural chromium with low-energy protons.
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•

Chemical isolation was performed using a published method that involved
digesting the chromium target in HCl, replacing the HCl with dilute H2SO4
and then immobilizing

52

Mn(II) on a cation-exchange column. This method

resulted with visible amounts of Cr(III) in the product.
•

Chemical isolation using a recently published method was more effective.
This method involved digesting the chromium target in HCl, diluting this
solution in ethanol, immobilizing 52Mn(II) on an anion-exchange column, and
performing this process repeatedly.

•

Recommended future directions: Trace metal analysis after each round of the
anion-exchange separation method to determine how many rounds are
necessary; characterization of routine production including cyclotron yields,
chemical recovery percentage, radionuclidic purity, and trace metals analysis.

Chapter 3. Biodistribution and PET Imaging of 52Mn
•

Biodistribution studies of intravenously injected

52

Mn(II) in mice showed

uptake in many organs, most interestingly: salivary glands, brain, thyroid,
thymus, pancreas, liver, kidney, and bone.
•

Similar studies in rats that extended to longer timepoints showed that activity
in all of those organs decreases significantly over the course of seven days,
except for brain, adrenals, and pancreas and confirmed that manganese is
excreted almost exclusively through the feces and not the urine.

•

Biodistribution studies of inhaled manganese in mice showed uptake in lung,
brain, thyroid, pancreas, liver, and kidney.

146

•

PET imaging of [52Mn]MnCl2 in mice and rats confirmed the observations
from biodistribution, including high signal from 52Mn in the pancreas at seven
days post-injection, after the activity had significantly decreased in nearby
tissues, such as the liver and kidneys.

•

Recommended future directions: PET/CT imaging using a CT contrast agent
that will reveal the pancreas on CT, which will enable quantitative imaging of
free manganese in the pancreas with possible applications in diagnostic
imaging of diabetes.

Chapter 4. Applications for 52Mn in PET/MR Imaging
•

A

phantom

containing

various

concentrations

of

non-radioactive

Mn(II)Cl2·(H2O)4 dissolved in water ,was imaged by MRI using an inversion
recovery pulse sequence. The signal from the images were analyzed, and these
results were used to calculate the relaxivity of this compound in aqueous
solution.
•

Another phantom was constructed that contained a matrix of different
concentrations of non-radioactive Mn(II)Cl2·(H2O)4 dissolved in water to
which different amounts of 52Mn had been added. This phantom was imaged
by PET/MR and revealed changes in both MR and PET signals.

•

Recommended future directions: Investigate the utility of

52

Mn by

radiolabeling a compound that has been used to chelate Mn(II) for MRI
imaging; perform PET/MR imaging of phantoms containing the compound

147

complexed with non-radioactive Mn(II) and radioactive

52

Mn(II) in various

concentrations and radioactivities.

Chapter 5. Remotely-Controlled Modules for the Isolation of PET Radiometals
•

Semi-automated modules for the scaled-up production of

89

Zr and

86

Y were

constructed in collaboration with a team of people. These automated modules
were able to carry out separations inside of a lead hot cell by moving solvents
through tubing by vacuum or compressed air. The separation process was
controlled from outside the hot cell by a laptop that was connected to the
module and running a software program that was produced in-house. The
ability to control separation processes remotely protects production personnel
from significant radiation dose, and these modules have been used routinely to
produce isotopes for use at institutions nationwide, including

89

Zr for a

clinical trial at our institution.
•

We have designed a similar module that will implement the anion-exchange
separation method for 52Mn from a chromium metal target.

•

Recommended future directions: For the

52

Mn automated module: assemble

the module; automate with a custom software program; validate the module
with increasing starting activities until it is ready for routine use; if collecting
the final

52

Mn product in the same glass vessel as the previous rounds

introduces contaminants in the final product, then a separate line and
collection vessel for the final round of elution of
design.
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52

Mn can be added to the

This dissertation has presented preliminary work in the production and biomedical
applications of

52

Mn, a radionuclide that holds potential for many more studies related to PET

imaging and non-imaging of the behavior of manganese.
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Appendix A. Calibration Setting Numbers
for Selected PET Radioisotopes in
Ionization Dose Calibrators1,2,3,4

For PET radionuclides, the radioactivity of a sample can be conveniently measured by a
dose calibrator. These devices depend on a “calibration setting number”, but many recommended
settings from manuals were interpolated based on standard sources of other radionuclide(s). We
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conducted HPGe gamma-ray spectroscopy, resulting in a reference for determining settings in
two types of vessels containing one of several PET radionuclides. Our results reiterate the notion
that in-house, experimental calibrations are recommended for different radionuclides and vessels.

A.1. Introduction
Many PET imaging agents that are currently in development, including peptides,
antibodies, and nanoparticles, have biological half-lives of hours to days, so they require
positron-emitting radiolabels with longer half-lives than traditional PET isotopes, such as 11C or
18

F. Other isotopes such as 64Cu, 86Y, 89Zr, and 124I, satisfy these criteria and are currently used as

radiolabels for compounds in preclinical and clinical research (Ikotun and Lapi, 2011; Nayak and
Brechbiel, 2009; Wadas et al., 2010). For studies using any of these isotopes, it is critical to
obtain accurate measurements of radioactivity at numerous stages of the PET study, including:
immediately following target irradiation, chemical separation, dispensing, radiolabelling, and
pre-injection. These radioactivity measurements are commonly measured in laboratory and
clinical settings using a dose calibrator, which provides fast results for the measurement of the
radioactivity of a sample. This type of benchtop instrument has a small enough footprint and a
small enough cost to be commonly installed in many different rooms that might be used during
the workflow from cyclotron to injection.
The user manuals provided by Capintec (2007, 2015) for the dose calibrators that were
used in this investigation provided a good explanation of the physics of radiation measurement
that are employed by these models of gas ionization dose calibrators. We only briefly summarize
these explanations here. Dose calibrators measure the radioactivity of a sample based on the rate

2

at which it emits ionizing photon radiation—X-rays, gamma-rays, or other photons (e.g., from
positron annihilation). With a few exceptions, particle radiation—alphas, betas, and positrons—
are not penetrating enough to cause ionization in the gas chamber. In many models of dose
calibrators, the radioactive sample is lowered into the center of a cylindrical sealed chamber
containing a gas. Photons in the 100-2,000 keV energy range do not directly produce the
ionization signal for the dose calibrator, but rather they interact with the wall and/or gas of the
chamber to release electrons, and these secondary electrons ionize the gas in the chamber enough
to produce the electric signal that is measured by the device. Electric current is created in a
circuit within the dose calibrator, and the magnitude of this current is directly proportional to the
radioactivity of the isotope that emitted the radiation (for similar sample geometries). In the dose
calibrators used in this investigation, the gas in the chamber was argon, which is also used in
many other gas ionization dose calibrators.
Since the radiation dose rates vary widely by isotope, the accuracy of these instruments
relies on using the correct calibration setting for the isotope being measured. For ionization
chambers connected to older, analog control units, a dial setting adjusts a potentiometer to
change the gain in the detector for the isotope being measured (IAEA). In newer, digital dose
calibrators, a “calibration setting number” (represented by the variable NA in certain user
manuals) simply adjusts the digital output of the unit (Capintec, 2007, 2015; Chandra, 2011). In
both generations of dose calibrators, numerous commonly used isotopes have pre-programmed
settings that can be selected, but a custom calibration setting number must be entered (or dialed)
for other isotopes. Many calibration setting numbers are recommended by Capintec in user
manuals, but the vast majority of these values were calculated using an empirical linear fit
equation that was based upon the detector response to only two isotopes in a single geometry

3

(Capintec, 2007, 2015). Specifically, these measurements were conducted for reference sources
consisting of 5 mL of solution containing

57

Co or

60

Co in a glass ampoule with 0.6 mm wall

thickness, obtained from the United States National Institute of Standards and Technology
(NIST) (NIST, 2011; Capintec, 2007, 2015).
Consequently, several publications have endeavored to experimentally determine new
calibration setting numbers for various models of Capintec dose calibrators, sample geometries,
and radionuclides. To measure reference activities, these investigations have used various
radioanalytical techniques: HPGe detector (Beattie et al., 2014; Coursey et al., 1993;
Zimmerman et al., 2001), NaI(Tl) detector (Zimmerman et al., 2002), 4πβ liquid scintillation
(4πβ-LS) (Cessna et al., 2008; Mo et al., 2006; Zimmerman and Cessna, 2000; Zimmerman et
al., 1999), or a different gas ionization chamber (Tyler and Woods, 2002, 2003). Some of the
calibration setting numbers that were determined in these studies yielded radioactivity readouts
that were dramatically different from the radioactivity readout from recommended settings. In at
least one case, Capintec officially changed its recommended calibration for an isotope: Based on
the results of Zimmerman, et al. (2001) and later Cessna, et al. (2008), the recommended setting
number for

18

F was changed from 439 to 472 for NIST ampoules and 484 for 3 mL plastic

syringes (Capintec, 2009). Furthermore, the calibration setting numbers for the same isotopes in
the same dose calibrator models were often greater for samples with larger volumes. Geometry
effects are even more pronounced for isotopes that emit low-energy gamma-rays (Tyler and
Woods, 2003); or positrons or beta particles (Capintec, 2007, 2015) because these radiations are
more susceptible to systematic errors resulting from attenuation or scattering, respectively.
We acknowledge that some facilities in radiochemistry and nuclear medicine may rely
solely on Capintec dose calibrators to measure radioactivity—without access to a high-precision

4

reference measurement instrument, such as a HPGe detector. In Section A.2.3, we performed
gamma-ray spectroscopy using a HPGe detector to quantify the amount of radioactivity in
samples that served as references for the experimental determination of calibration setting
numbers for two different sample geometries containing the PET isotopes 52Mn, 64Cu, 86Y, 89Zr,
76

Br and

124

I. The two geometries that we tested were 2 mL microcentrifuge tubes, which are

widely measured in dose calibrators for radiochemistry work, and 10 cc (10 mL) syringes, which
are commonly measured in dose calibrators before injection of a radiopharmaceutical.

A.2. Experimental
A.2.1. Materials
Ultrapure water (~18 MΩ) was obtained from a Millipore system (Billerica,
Massachusetts, United States) and was used for diluting aliquots of radioactivity. 2 mL
microcentrifuge tubes and 10 cc syringes were purchased from Fisher Scientific (Pittsburgh,
Pennsylvania, United States). All

124

I was purchased from 3D Imaging (Maumelle, Arkansas,

United States).

A.2.2. Radionuclide Production
All other isotopes used in this work were produced on-site by (p,n) reactions in solid
targets that were bombarded with protons from the CS-15 cyclotron (The Cyclotron Corporation,
Berkeley, California, United States) at Washington University School of Medicine in St. Louis
(WUSM). Various methods (Table A.1) were carried out by remotely-controlled automated

5

modules inside of lead hot cells to separate the following isotope products from the
corresponding bulk solid target material: 64Cu (Kume et al., 2012; McCarthy et al., 1997), 76Br
(McCarthy et al., 1999; Tolmachev et al., 1998),
2005), and

89

86

Y (Avila-Rodriguez et al., 2008; Yoo et al.,

Zr (Holland et al., 2009; Meijs et al., 1994; Wooten et al., 2012). Manganese-52

was produced by bombarding a natural Cr foil target with protons (Wooten et al., 2015),
followed by digesting the Cr foil in hydrochloric acid with no further purification. Iodine-124
was produced by 3D Imaging (Berridge, 2013) in a manner similar to methods that were
published by Knust, et al. (2000), Sheh, et al. (2000), and other published methods. For each
isotope, aliquots were taken and diluted with ultrapure water as needed for gamma-ray
spectroscopy (Section A.2.3) or dose calibrator measurements (Section A.2.4).

Table A.1. Summary of isotope production methods that were followed or adapted for the
isotopes used in this work.
Product
Isotope
52
Mn
64

Cu

76

Br

86

89

Y

Zr

124 †

I

Isolation Method

Reference(s)
-

Electroplated
64
Cu metal
Pressed 76Cu2Se
pellet

(No isolation performed—only
digestion of Cr target by HCl.)
Anion-exchange
chromatography
Dry distillation followed by
thermal chromatography

86

Pressed 86SrO
pellet

pH-based precipitation
followed by filtration

89

nat

Hydroxamate resin
chromatography

Isotope
52
Cr
(83.7%)
64
Ni
(0.9%)
76
Se
(9.4%)
Sr
(9.9%)
Y
(100%)
124

Te
(4.7%)

Target
Material
nat
Cr metal foil

Y metal foil

TeO2/Al2O3

Dry distillation

AM: (Kume, et al., 2012)
SC: (McCarthy et al., 1997)
AM: Not yet published.
SC:
(McCarthy, et al., 1999)
(Tolmachev, et al., 1998)
AM: Not yet published.
SC:
(Avila-Rodriguez, et al., 2008)
(Yoo, et al., 2005)
AM: (Wooten, et al., 2012)
SC:
(Holland, et al., 2009)
(Meijs, et al., 1994)
SC:
(Knust, et al., 2000)
(Sheh, et al., 2000)

All isotopes were produced via (p,n) reactions. †Purchased from 3D Imaging (Maumelle, Arkansas, United States).
All other isotopes were produced in-house at WUSM/MIR. AM: automated module; SC: separation chemistry.
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A.2.3. Gamma-Ray Spectroscopy
The radioactivity per volume of the product solution was calculated based on gamma-ray
spectroscopy results from one of two Canberra (Meriden, Connecticut, United States) brand
HPGe detector systems: Detector 1 (model GC1818 with 18.9% efficiency) and Detector 2
(model GC2018 with 24.5% efficiency) . Each detector was connected to a digital spectrum
analyzer (DSA; model: DSA-1000) and operated by the Gamma Acquisition & Analysis module
of the Genie 2000 spectroscopy software package (v. 3.3). The HPGe detector was calibrated for
energy and efficiency based on the full-absorption photopeaks from a mixed-gamma reference
source (Eckert & Ziegler Analytics, Atlanta, Georgia, United States). This calibration source
consisted of a 2 mL skirted microcentrifuge tube that contained eight radioisotopes in a hardened
epoxy, which was an identical geometry to the 2 mL microcentrifuge tubes used for counting
emissions from our diluted isotope products.
For each isotope considered in this study, an aqueous solution containing the isotope was
serially diluted in 2 mL microcentrifuge tubes until the Ge detector yielded a dead time <5%.
The dilution was produced in triplicate, and each of these three tubes was scanned long enough
to acquire ≥103 counts for the gamma-ray with the highest branching ratio, which was typically
10-30 min of detector live time. In the spectroscopy results, we identified at least one fullabsorption photopeak that corresponded to an identifying gamma-ray energy (Eγ) that was
emitted by the isotope being measured. Gamma-ray energy(ies) with the highest branching
ratio(s) without also being emitted by a metastable isomer (e.g., Eγ=1,434 keV from 52mMn) were
used for analysis. The number of counts and detector efficiency for the selected peak were used
to calculate the radioactivity per volume, assuming no decay during counting because the
counting period was short (<5%) relative to the isotope’s half-life using the following equation:

7
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!!
!! !! !!

,

(A.1)

where A is the radioactivity (Bq); Nc is the number of counts (net peak area) for the fullabsorption photopeak; εc is the counting efficiency for the detector at the corresponding gammaray energy (dimensionless); Iγ is the branching ratio for the corresponding gamma-ray
(dimensionless); tl is the detector live time during gamma-ray counting. The results calculated
using Equation A.1 were decay-corrected to an arbitrary time in the past for all three tubes,
averaged together, and then multiplied by the dilution factor to determine the radioactivity per
volume of the original product solution at that common time. This value was then used to
calculate the radioactivity per volume in the product solution at the time when the samples would
be prepared for the dose calibrator measurement (Section A.2.4).

A.2.4. Dose Calibrator Measurements
Calibration setting numbers were determined from measurements using two models of
dose calibrators from Capintec (Ramsey, New Jersey, United States): a model CRC-15R or a
model CRC-25R. Characteristics of both of these models are given in Table A.2, and they use
identical calibration setting numbers (Capintec, 2007, 2009, 2015). For each isotope, one
radioactivity between 10-1,000 µCi was selected for measurement in a dose calibrator. Based on
the radioactivity per volume calculated from the gamma-ray spectroscopy results, the
radioactivity was decay-corrected to the approximate time of measurement in the dose calibrator.
Then, the appropriate volume containing the radioactivity was transferred into either a 2 mL
microcentrifuge tube or into a 10 cc syringe. The final volume in these vessels was

8

approximately 1 or 8 mL, respectively. The time from pipetting to the end of the final
measurement in the dose calibrator was less than 15 min., so decay during that period was
negligible for the isotopes studies.

Table A.2. Shared characteristics of the CRC-15R and CRC-25R models of Capintec brand
ionization dose calibrators.
Well Diameter
Well Depth
Electrometer Accuracy
System Precision
System Linearity
Equation for recommended calibration numbers

6.1 cm
25.4 cm
Better than ±2%
Better than ±0.1% FSD
Within ±2%
NA = 1076*(RA – 0.080)

NA=Calibration number; RA=the response of the detector to Isotope A. (Sources: Capintec, 2007,
2015).

Each sample was placed in the dose calibrator, and the calibration setting number was
adjusted until the screen displayed the expected radioactivity based on the gamma spectroscopy
results (corrected for dilution and radioactive decay). During these measurements, the precision
of the dose calibrator was set to read to the nearest 1 µCi. For some isotopes that emitted high or
low dose rates of gamma radiation, it was necessary to find a calibration setting number that
caused the control unit to display a multiple of the expected value so divisions or multiplication
of the readout by an integer correction factor obtained a meaningful result. When using these dial
settings to measure an unknown amount of radioactivity, the readout value would be divided or
multiplied by the correction factor for that isotope, such as ÷2, ×2, ×10, and ×100, to yield the
final radioactivity readout (ARO). For some of our experiments, the sample was removed from the
dose calibrator and replaced in a different orientation to account for variations in the positioning
of the vessel within the well of the dose calibrator. For these experiments where only one valid
setting was recorded, we conservatively assumed an uncertainty of ±5 setting numbers to

9

52

manufacture a range of values. Additionally, for

Mn,

64

Cu, and

124

I, the calibration setting

number was varied over a large range to observe the effect on radioactivity readout on a wider
scale.

A.2.5. Data and Uncertainty Analysis
The entire dose calibrator had an instrumental uncertainty of ±2% (Capintec, 2007,
2015). Since the radioactivity is directly proportional to the radioactivity readout in the local
range of calibration setting numbers, we calculated 2% of the maximum in each range, and
added or subtracted it to the maximum or minimum of each range to get new values, !!!"# and
!!!"# . If the displayed value needed to be multiplied or divided by a scaling factor, the number
was adjusted by 2% and by the same scaling factor. The midpoint of this new range, !!!"# , was
calculated as the mean of !!!"# and !!!"# for that trial, and the uncertainty of this midpoint was
(!!!"# - !!!"# )/2. If the vessel was placed in the dose calibrator multiple times, the midpoints
from each placement were averaged. The uncertainty in this mean resulted from propagating the
individual uncertainty from each placement using the following equation:

!!! ! =

! !
!

!
!
!!! !!!!

,

(A.2)

where !!! is the uncertainty in the average; n is the number of trials; and !!!! is the uncertainty
in each value that was averaged together. Equation A.2 applies the total differential equation for
the propagation of small uncertainties to the equation for the arithmetic mean, if all uncertainties
are uncorrelated (Arras, 1998; Croarkin; Ku, 1966).
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Dose calibrator measurements were performed on vessels in triplicate, each resulting in
an average result with uncertainty. These results across the three vessels were averaged, and the
uncertainty in each final result was obtained by propagating the uncertainties from the individual
vessels through Equation A.2 (This time, with n=3.). The final average result was rounded to the
nearest integer (because all dial settings are integers), and the uncertainty was accordingly
rounded up to the nearest integer to be conservative. These results are the final values and
uncertainties that are shown in Table A.3.

A.3. Results
Our results for calibration setting numbers for the Capintec dose calibrators are shown in
Table A.3 for our six isotopes, both in 2 mL microcentrifuge tubes and in 10 cc syringes. Table
A.3 also shows the gamma factor (Γ) for each of these isotopes, calculated by Smith and Stabin
(2012) to express the dose rates for various isotopes based on a weighted average of gamma-ray
energies and branching ratios—including annihilation photons. All results were greater than the
recommended values found in the user manuals to varying degrees. This was interesting because
the recommended values were interpolated from results based on 5 mL calibration sources,
which would be near the midpoint of the two volumes.
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Table A.3. Results for calibration setting numbers on Capintec CRC-15R and CRC-25R
dose calibrators.
Isotope

Gamma Factora

From Manualb

Γ (R·cm2/mCi·h)
52

Mn

64

Cu

2 mL Tube

10 cc Syringe

Percent Difference
in Radioactivity Readout
(%)

New Calibration Setting

18.4

676÷2

759±12 (÷2)

777±13 (÷2)

+10.2%

1.05

15 or

16±2

108±2 (x2)

-3.6%c

115 (×2)
76

Br

14

495÷2

604±9 (÷2)

800±9 (÷2)

+52.6%

Y

18.9

711÷2

762±12 (÷2)

815±9

-44.1%

Zr

6.59

465

514±6

527±6

+11.2%

6.59

570

29±1

733±7

+24.6%

86
89

124

I

For (x2) or (÷2), the radioactivity readout from the dose calibrator should be multiplied or divided
by 2 to obtain the correct radioactivity measurement. aGamma factor describes the dose rate from
gamma radiation emitted by an isotope. (Data from: (Smith and Stabin, 2012).) bAll recommended
dial settings were the same in the manuals for both the CRC-15R and CRC-25R models, except
for 76Br and 89Zr (not listed in the manual for the CRC-25R). (Recommended setting(s) from:
Capintec, 2007, 2015). cCalculated relative to the radioactivity readout using setting: 15.

For comparison, we measured each of the isotopes in a 10 cc syringe using our result for
the calibration setting number and also the recommended value, and the percent difference
relative to the measurement using the new value was calculated. These percentages of difference
varied significantly (Table A.3), and other published works reported (Table A.4) that activities
measured using recommended calibration setting numbers can differ slightly (~1-10%) or
greatly: +50% for

90

Y (Coursey et al., 1993); +45% and -42% for

(Zimmerman et al., 2002); and +35% for

111

125

I in different geometries

In (Ceccatelli et al., 2007). In the majority of

published studies listed in Table A.4, the radioactivity measured using recommended settings
would overestimate the amount of radioactivity that was present in the sample.
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Table A.4. Selected results from other studies that determined setting numbers for various
medical radionuclides and models of Capintec dose calibrators.

Isotope

18

Reference

(Cessna, et
al., 2008)

F

Method

4πβ-LS
"
"
"

(Mo, et al.,
2006)
(Zimmerman,
et al., 2001)
(Zimmerman
and Cessna,
2000)

89

(Beattie, et
al., 2014)
(Coursey, et
al., 1993)

Zr

90

Y

4πβ-LS

Capintec
Model1
CRC15R
CRC15R
CRC15PET
CRC-12
CRC712M

HPGe

CRC-12

"

CRC35R

4πβ-LS

CRC-12

"

CRC-12

HPGe

CRC15R

HPGe

CRC-12

Vessel
Geometry

Source
Vessel
Volume
Vvessel
(mL)

Liquid
Volume
Vsource
(mL)

Result
Setting
Readout
Number2 Difference3
NA (-)

(%)

NIST
ampoule

5

5

472

+6.4

Syringe

3

1

484

+8.9

"

"

"

501

+12.7

"
Wheaton
vial
Monojet
syringe
NIST
ampoule

"

"

500

+13.3

-

-

459

-

12

9

482

+8.3

-

-

477

+6.2

10

5

463

+4.5

12

9

482

+7.3

20

10

517

+8.00-12.0

-

-

48 (×10)

+50

20

10

494
(with Cu
filter)

+14.9-28.0

5

-

497

+45

2

-

143

-42

Mallinckrodt
dose vial
plastic
syringe
borosilicate
glass vial
NIST
ampoule

124

I

(Beattie, et
al., 2014)

HPGe

CRC15R

125

I

(Zimmerman,
et al., 2002)

NaI(Tl)

CRC-12

"

CRC-12

4πβ-LS

CRC-12

Dupont dose
vial

3

-

181

-2.7

"

CRC-12

NIST
ampoule

-

-

184

-1.7

4πβ-LS

CRC-12

SoloPak
dose vial

5

-

620
(×10)

+22.2

4πβ-LS

CRC-12

NIST
ampoule

-

-

630
(×10)

+30

133

(Zimmerman
and Cessna,
2000)

Xe

188

(Zimmerman
and Cessna,
2000)
(Zimmerman,
et al., 1999)

Re

borosilicate
glass vial
plastic
syringe
conical glass
dose vial

1

All dose calibrator models were by Capintec. These results for calibration setting numbers may
translate across certain models of Capintec dose calibrators, but not necessarily all models. 2Some
calibration setting numbers require that the radioactivity readout be multiply or divided by a factor
for an accurate measurement. 3This column is the percentage difference of the radioactivity
readout using the calibration number from the user manual versus the radioactivity readout using
the experimentally determined calibration number.
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A.4. Discussion
For selected isotopes and geometries, the radioactivity readout over a wide range of
calibration setting numbers was also recorded. These data were plotted in Figure A.1 and
demonstrate something similar to an inverse relationship of ARO to NA across small and large
ranges for NA. These isotopes represented a variety of gamma-ray dose rates, such as 52Mn, 64Cu,
and

124

I, all in 2 mL microcentrifuge tubes. Readout radioactivity was normalized to the largest

value that was measured using the calibration setting numbers in that experiment for that
radionuclide. It is important to be aware of these relationships because the fitted equations can be
used to calculate the correct radioactivity of a sample in case the incorrect setting is accidentally
used in a measurement. Therefore, when using the dose calibrator, the calibration setting number
used should be recorded in case rescaling is necessary in the future.

Figure A.1. Plots of normalized readout radioactivity (ARO,norm) versus calibration setting
numbers (NA) over large ranges of settings.
Readout radioactivity was normalized to the largest value that was measured using the calibration
setting numbers in that experiment for that radionuclide. Over large ranges for three isotopes with
very different total gamma-ray dose rates: 52Mn, 64Cu, and 124I. All results in this figure were from
samples in 2 mL microcentrifuge tubes.
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Using gamma-ray spectroscopy results as a reference, calibration setting numbers for
using Capintec dose calibrators to measure the radioactivity of six PET isotopes:
76

Br, 86Y, 89Zr, and

124

52

Mn,

64

Cu,

I were determined experimentally for 2 mL microcentrifuge tubes and 10

cc syringes. In many cases, results were significantly different from the calibration setting
numbers recommended by the manufacturer. Since the CRC-15R and CRC-25R models of dose
calibrators from Capintec were used, results can be used directly for that family of models,
including: 15R, 15W, 25R, 25W, 127R, and Ultra-R (Capintec, 2009). However, since the
manufacturer’s recommended settings are interpolated from other measurements that used a
standard glass NIST source geometry, and because results show significant effects of sample
geometry for several isotopes, we recommend utilizing a reference sample or high-precision
reference measurement—such as HPGe gamma spectroscopy—to experimentally determine
calibration setting numbers for various geometries and materials involving dose calibrator use.
In most cases, calibration setting numbers differed from those recommended in the user
manual, which meant that using the recommended calibration settings could result in
radioactivity measurements higher or lower than expected. Additionally, settings determined for
the 10 cc syringes were consistently greater than for the 2 mL geometry. Our results reiterate the
widely known fact that experimentally determined dose calibrator settings for various
radionuclides and sample geometries are necessary for accurate measurements of radioactivity.
These settings have potentially significant implications for radiochemistry experiments, as well
as dosimetry for pre-clinical and clinical applications of radionuclides, including the PET
radionuclides that were examined in this work.
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A.5. Conclusions and Recommendations
Using gamma-ray spectroscopy results as a reference, we have experimentally
determined calibration setting numbers for using certain Capintec dose calibrators to measure the
radioactivity of six PET isotopes:

52

Mn,

64

Cu,

76

Br,

86

Y,

89

Zr, and

124

I. Measurements were

conducted for 2 mL microcentrifuge tubes and 10 cc syringes to provide results for two vessels
that are commonly placed in dose calibrators to measure radioactivity for either radiochemistry
lab work or for in vivo injections, respectively. In many cases, our results were significantly
different from the calibration setting numbers recommended by the manufacturer. As the CRC15R and CRC-25R models of dose calibrators from Capintec were used, our results can be used
directly for that family of models, including: 15R, 15W, 25R, 25W, 127R, and Ultra-R
(Capintec, 2009). However, since the calibrations settings recommended by the manufacturer are
interpolated results based on measurements using a different source geometry than what is
commonly used in practice for clinical and pre-clinical radiochemistry. Since our results show
significant effects of sample geometry, we join with a body of literature to recommend
performing in-house calibration for any radionuclide or vessel geometry by utilizing a highprecision measurement, such as HPGe gamma spectroscopy, as a reference for cross-calibration.
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